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Abstract
Current understanding of how diseases are associated with each other is
mainly based on the similarity of clinical phenotypes. However, without
considering the underlying biological mechanisms of diseases, such knowl-
edge is limited and can even be misleading. With a growing body of tran-
scriptomic, proteomic, metabolomic and genomic data describing diseases,
we proposed to gain insights into diseases and their relationships in the
light of large-scale biological data. We modelled these data as networks of
inter-connected elements, and developed computational methods for their
analysis.
We exploited systematic measures based on graphlets to uncover bio-
logical knowledge from network topology. Since recently some doubt had
arisen concerning the applicability of graphlet-based measures to low edge
density networks, we first evaluated the use of graphlet-based measures and
demonstrated their suitability for biological network comparison. We also
validated the use of graphlet-based measures for finding well-fitting random
models for protein-protein interaction (PPI) networks, and demonstrated
that five viral PPI networks are well fit by several theoretical models not
previously tested.
To gain novel insights into diseases and their relationships, we integrated
different types of biological data and developed computational approaches
to compare diseases based on their underlying mechanisms. We applied sev-
eral similarity measures including standard methods and two novel network-
based measures to estimate disease association scores. We showed that
disease associations predicted by our measures are correlated with associa-
tions derived from standard disease classification systems, comorbidity data,
genome-wide association studies and literature co-occurrence data signifi-
cantly higher than expected at random, demonstrating the ability of our
measures to recover known disease associations. Furthermore, we presented
case studies to validate the use of our measures in identifying previously
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undiscovered disease associations. We believe novel associations uncovered
in our studies can enhance our knowledge of disease relationships, and may
further lead to improvements in disease diagnosis and treatment.
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1. Introduction
Correct classification of diseases is critical for effective diagnosis, treatment
and prevention of diseases. Therefore, disease classification has become key
to modern biology and medicine. The current standard disease classifica-
tion system is the International Classification of Diseases (ICD), which has
been used worldwide for general epidemiological and health management
purposes [1]. Other commonly used classifications include Medical Subject
Headings (MeSH) [2], Systematized Nomenclature of Medicine (SNOMED)
[3] and Unified Medical Language System (UMLS) [4]. However, current
knowledge of disease classification is still mainly based on the similarity
of clinical phenotypes, focusing on symptoms of affected organs. Without
considering the molecular mechanisms driving diseases, such knowledge is
limited and can even be misleading. For example, a common phenotype can
be caused by different underlying mechanisms, while a common mechanism
may lead to various phenotypes. Further understanding of how diseases
are associated with each other based on molecular-level biological data is
expected to lead to improvements in disease diagnosis, prognosis and treat-
ment.
During the past decade, advances of ‘omics’ technologies has lead to a
wealth of molecular-level biological data. These data, including genetic data
(e.g., genome-wide association study [GWAS] data), genomic data (e.g., mi-
croarray data), proteomic data (e.g., protein-protein interaction [PPI] data),
metabolomic data (e.g., metabolic pathways) and transcriptomic data (e.g.,
RNA-Sequencing data), have provided great opportunities for us to improve
current understanding of cellular systems as well as the underlying mecha-
nisms driving diseases. Many of these biological data have been modelled
as networks, in which nodes represent elements of biological systems such
as proteins and genes, and edges between nodes represent the associations
between these biological elements. For example, a PPI network models the
physical interactions between proteins in a cell, where a node represents a
16
protein and an edge exists between two nodes if the corresponding proteins
can physically bind to each other. As most biological networks are large
and complex, it is necessary to develop efficient and biologically meaningful
algorithms for their analysis.
Systematic approaches based on graphlets (small, connected, induced sub-
graphs of large networks) have been introduced to measure the structure
(also called topology) of biological networks [5, 6]. Graphlet-based measures
are proving useful in many network research tasks, including network mod-
elling [7, 8], network comparison [5, 6], and network alignment [9, 10, 11, 12].
Recently some doubt has arisen concerning the applicability of graphlet-
based measures for biological network comparison: it has been claimed that
the measures are ‘unstable’ in regions of low edge density [13]. In addi-
tion, it has also been claimed that there is no existing network model that
matches the structure found in PPI networks [13].
In the rest of the thesis, we first give a review of related works in Chapter
2. Topics such as biological data, network modelling and comparison, re-
lated studies on disease associations, are explained in that chapter. We then
examine the use of graphlet-based measures for biological network compari-
son in Chapter 3. We identify the edge density regions in which the topology
of model networks is ‘unstable’, and show how graphlet-based measures cor-
rectly detect this topological instability. Moreover, by investigating recent
PPI networks of different species, we show that these ‘unstable’ regions do
not affect the analysis of current PPI networks, as current PPI networks are
dense enough to avoid these regions. Furthermore, we validate the use of
graphlet-based measures for finding well-fitting random models for PPI net-
works, and show for the first time that five viral species, possessing the latest
and most complete PPI networks, are well-fit by several network models.
To gain novel insights into diseases and their relationships, we take ad-
vantage of diverse biological data and develop computational methods to
compare diseases by considering their underlying mechanisms. In Chapter
4, we first analyse four publicly available disease-gene association datasets,
and apply three disease similarity measures, namely annotation-based mea-
sure, function-based measure and topology-based measure, to estimate the
association scores between diseases. By systematically evaluating our sim-
ilarity measures against the ICD classification, a statistical measure of co-
morbidity and disease associations derived from GWAS data, we show that
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disease associations predicted by our measures are correlated with known
disease associations significantly higher than expected at random.
In Chapter 5, we further our results by integrating different types of large-
scale biological data, including GWAS data, disease-chemical associations,
biological pathways and Gene Ontology (GO) annotations, with the aim
to gain more complete understanding of the relationships between diseases.
In particular, we integrate these data into a heterogeneous network, where
nodes are bio-entities (e.g., genes, diseases, chemicals, pathways and GO
terms) and edges between nodes represent their associations. We extend
our disease similarity measures to an integration-based measure to predict
novel disease associations by mining the heterogeneous network. Our results
are systemically evaluated against the MeSH classification and a statistical
measure of disease co-occurrence in PubMed. In addition, we show that
our similarity measure achieves better performance by using the integrated
data than solely using a specific type of data. To illustrate the use of our
approach to uncover novel diseases associations, we present a case study of
Crohn’s disease, in which we identify its top associated diseases and validate
our predicted associations via mining the literature. We also give examples
to demonstrate how our approach can be used for drug repositioning.
Finally, in Chapter 6 we summarise the conclusions of this thesis. Discus-
sions of future research plans are also covered in that chapter. Other related
work of the thesis, such as supplemental materials of Chapter 3, Chapter 4
and Chapter 5, can be found in the appendix.
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2. Background
Networks have been used to represent many large-scale biological data. In
graph theory, a network (or a graph) consists of a set of objects, called nodes,
along with a set of links connecting them, called edges. There exist many
different types of biological networks, such as PPI networks which model
the physical interactions among proteins and gene regulation networks which
model the regulation of gene expression in a cell. As most of these biological
networks are large and complex, it is necessary to develop efficient and
biologically meaningful algorithms for their analysis.
In this chapter, we first give an overview of different types of biologi-
cal data, including PPIs, biological pathways, disease-gene associations and
drug-target associations, along with explanations of how these data can be
modelled as biological networks. We also introduce graph theoretic termi-
nologies and concepts, and review the major challenges of biological network
research. In particular, we discuss the global network properties and local
network properties, and show the use of these network properties for net-
work modelling and network comparison. Furthermore, we discuss current
disease classification systems and review the literature of related studies on
predicting disease-disease associations.
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2.1. Biological data
2.1.1. Protein-protein interactions
Proteins are large biological molecules that play a central role in most molec-
ular processes in a cell. They catalyse metabolic reactions, replicate DNA,
transport molecules, defend antigens and transmit messages from cell to
cell. An interaction between two proteins occurs when they physically bind
to each other to perform a biological function. Studying PPIs is expected
to provide valuable insights into human diseases, which may lead to the
development of new therapeutic approaches [14].
Two methods that have commonly been used to detect PPIs are yeast
two-hybrid (Y2H) screening [15, 16, 17, 18, 19, 20, 21] and Mass Spectrom-
etry (MS) of purified complexes [22, 23, 24, 25]. Compared to traditional
small-scale biochemical techniques, they are more standardised, and provide
a more comprehensive view of the entire interactome. Using these methods,
recent studies have published partial PPI networks for many organisms,
including viruses (e.g., herpes simplex virus [26]), prokaryotes (e.g., Es-
cherichia coli [27]), and eukaryotes (e.g., yeast [16, 25, 24], nematode worm
[28, 20], fruit fly [29], and human [18, 19]). These PPI data are now pub-
licly available in several databases including the Biological General Reposi-
tory for Interaction Datasets (BioGRID) [30], the Human Protein Reference
Database (HPRD) [31], the MIPS Mammalian Protein-Protein Interaction
Database (MIPS) [32], the Molecular Interaction database (MINT) [33], the
Interologous Interaction Database (I2D) [34, 35], the Database of Interact-
ing Proteins (DIP)[36] and IntAct [37].
PPIs can be modelled as networks. In a PPI network, a node repre-
sents a protein and an undirected edge exists between a pair of nodes if
the corresponding proteins can physically bind to each other (Figure 2.1).
During the past decade, the topology of PPI networks has become a popular
subject of research. It has been shown that the topology of PPI networks
could be used to uncover novel insights into evolution [38, 39, 11], diseases
[14, 40, 41, 42], and gene functions [43, 44, 45, 46, 39].
Due to limitations in experimental techniques, current PPI networks are
still noisy and largely incomplete. Studies have suggested that current PPI
networks have high false-positive rates and even higher false-negative rates
[49, 50, 51]. For example, it is claimed that the estimated false positive rates
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(a)
(b)
Figure 2.1.: (a) A schematic representation of a PPI network. This figure is
taken from [47]. (b) A PPI network of Arabidopsis thaliana with
2,634 nodes and 5,529 edges. PPIs are obtained from Arabidop-
sis Interactome Mapping Consortium (2011) [21]. Cytoscape
2.8.1 [48] was used for the visualisation.
of PPI networks constructed from Y2H screening data are in the range of
25% to 45%, and the estimated false negative rates are in the range of
75% to 90% [51]. Current PPI networks also contain the sampling and data
collection biases [52, 53, 47]. For example, some proteins that are relevant to
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human diseases are better studied than the others [47]. For these reasons,
there are still many difficulties and challenges in uncovering biologically
meaningful knowledge from PPI networks.
2.1.2. Biological pathways
A biological pathway represents an ordered series of actions among molecules
(mostly proteins and small chemical compounds) in a cell. It models how
molecules interact with each other to carry out biological functions. Current
knowledge of biological pathways is mainly extracted from the scientific lit-
erature by experts, and stored in repositories such as Kyoto Encyclopedia of
Genes and Genomes (KEGG) [54], Reactome [55], and WikiPathways [56].
Knowledge of biological pathways allows researchers to identify pathways
involved in a disease and identify which step of a pathway is affected in a
patient who has the disease, thus pathway data have been widely used to
provide insights into the underlying mechanisms of human diseases (e.g.,
[57, 58]).
There exists different types of biological pathways. Three of the most
common pathways are those involved in metabolism (represented by metabolic
networks), those involved in gene expression and regulation (represented by
gene regulation networks) and those involved in signal transduction (repre-
sented by cell signalling networks).
Metabolic network
Metabolic pathways model the metabolism, which is the set of biochemical
reactions that allow living organisms to grow and reproduce, maintain their
structures, and respond to their environments. In a metabolic pathway, a
primary metabolite (a small molecule such as Amino acid) is transformed
into another metabolite(s) through a series of chemical reactions catalysed
by enzymes.
Metabolic pathways can be represented by metabolic networks. There
exists several different representations for metabolic networks, including
substrate network, reaction network, enzyme-centric network and substrate-
enzyme network (see [59] for a review of metabolic networks). For example,
in a metabolic network represented as a substrate network, a node represents
a metabolite and an edge between a pair of nodes represents the biochemical
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Figure 2.2.: An example of modelling a metabolic pathway (left) as an undi-
rected network (center and right). The pathway illustrates the
first two steps of glycolysis. The main metabolites are alpha-D-
glucose 6-phosphate (G6P), D-fructose 6-phosphate (F6P) and
D-fructose 2,6-bisphosphate (F2, 6BP). ATP and ADP are cur-
rency metabolites thus can be ignored when constructing the
substrate representation of the network (right). The two reac-
tions are catalised by phosphoglucose isomerase and PFKFB
dimers. The pathway data is obtained from Reactome [55].
reaction that converts one metabolite to the other. Figure 2.2 illustrates
an example of how to model a simple metabolic pathway as a substrate
network. The pathway can be first modelled as an undirected network if
all interacting metabolites are considered equally. Since currency metabo-
lites such as water, oxygen, adenosine triphosphate (ATP) and adenosine
diphosphate (ADP) normally perform as carriers, for many applications it is
useful to ignore them in order to produce biological meaningful results from
network analysis [60]. A simplified substrate representation of the metabolic
network can be further constructed by removing currency metabolites. Only
connections between the main metabolites are presented in the simplified
network.
Gene regulation networks
Gene regulation pathways model the regulation of gene expression in a cell.
Regulation of gene expression includes a number of cellular processes that
control the increase or decease of the production of gene products (proteins
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or RNAs). Several steps in the gene expression process can be regulated, in-
cluding transcription, RNA sliding, translation and post-translational mod-
ification. For example, in a transcription step, genes can interact with each
other indirectly to regulate the expression levels of mRNAs. This process
can be modelled as a transcriptional regulation network, in which nodes
are genes, and directed edges are interactions through which the products
of one gene affect those of another. For example, if a transcription factor,
which is the protein product of gene X, binds regulatory DNA regions of a
gene Y to regulate the production rate of gene Y ’s protein product, this
process can be modelled as a simple network which contains a directed edge
from node X to node Y (this example was first illustrated by Milo et al.
(2002) [61]). Due to limitations in experimental techniques, current gene
regulation networks are still largely incomplete. For example, it has been
estimated that only < 3% of the expected gene regulatory interactions of
human have been discovered [62].
Cell signalling network
Cell signalling pathways are ordered sequences of signal transduction reac-
tions in a cell. They model the complex communication system that governs
basic cellular activities. Signal transduction occurs when an extracellular
signal (e.g., a chemical) activates a receptor on the surface of a specific
cell. The receptor interacts with the external signal and alters intracellu-
lar molecules (e.g., proteins) to create a response. Errors in cell signalling
pathways may lead to diseases such as cancer and diabetes. Cell signalling
pathways can be modelled as a network in which nodes are genes and edges
represent the order of signal transduction reactions in the cell.
2.1.3. Disease-gene associations
One of the most commonly used forms of biological data for studying human
diseases is disease-gene association. A gene is said to be associated with a
disease, if mutations in that gene may lead to that disease. For example,
genes BRCA1 and BRCA2 are associated with inheritable breast cancer,
since it has been shown that up to 90% of inheritable breast cancers are
due to mutations in these two genes [63]. Disease-gene associations can
be obtained from large-scale knowledge-bases such as the Online Mendelian
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Inheritance in Man (OMIM) [64]. OMIM contains information about genetic
disorders and human genes, along with phenotype-genotype relationships
between them. It has been used in various disease-related studies (e.g.,
[65, 66, 67]). OMIM mainly focuses on mendelian disorders (i.e., disorders
caused by a mutation in a single gene), and until recently it started to
collect information about complex diseases. There also exist other disease-
gene association repositories that focus on different aspects of phenotype-
genotype relationships, such as the Comparative Toxicogenomics Database
(CTD) [68], which focuses on environmental chemicals’ effects on human
diseases, and Pharmacogenomics Knowledge Base (PharmGKB) [69], which
focuses on the impact of genetic variation on drug response.
Recent advances in GWAS studies have enabled the exploration of disease-
gene associations in a systematic way on a genome scale [70, 71, 72]. GWAS
examines the genome for single-nucleotide polymorphisms (SNPs) that oc-
cur more frequently in people with a particular disease than in people with-
out it. GWAS is considered to be one of the most robust routes for iden-
tifying genetic variations associated with diseases. Recently, several pub-
licly available repositories such as the National Human Genome Research
Institute (NHGRI) GWAS catalog [73] and the GWASdb [74] have been de-
veloped to collect and integrate GWAS data obtained from various studies
conducted by different research groups.
Disease-gene associations can be modelled as a bipartite network (see
Section 2.2.1 for the definition of ‘bipartite network’). In a disease-gene
association network, a node represents a known human disease or a disease-
related gene, and an edge exists between a disease node and a gene node
if that gene is known to be associated with that disease. Disease-gene as-
sociations play an important role in improving our current understanding
of molecular causes and underlying mechanisms of human diseases. Details
of how disease-gene associations have been used to uncover novel biological
knowledge will be discussed in Section 2.3.2.
2.1.4. Drug-target associations
Drugs are chemical substances that bind to and modify the actions of spe-
cific proteins [75]. These specific proteins are called targets. In the area of
drug discovery, a protein is druggable if it is known to or is predicted to
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bind to a drug. The subset of the 21,000 genes in the human genome that
code for druggable proteins are called the druggable genome [75]. Sometimes
a drug designed for a target may also bind to other unintended proteins,
causing side effects.
The knowledge of drug-target associations is of utmost importance in
drug discovery and development. Drug-target association data are avail-
able in several repositories, including Drugbank [76], PharmGKB [69], and
ChEMBL [77]. Similar to disease-gene associations, drug-target associations
can be modelled as a bipartite network (see Section 2.2.1), in which a node
is a drug or a protein, and an edge exists between a drug and a protein if
that protein is a target of that drug. Yıldırım et al. [78] constructed the
first drug-target network by using associations obtained from Drugbank. By
analysing the drug-target network along with a human PPI network, they
claimed that most drugs were palliative as they did not bind to proteins
corresponding to the underlying causes of human diseases [78]. Drug-target
associations have also been used for target identification [79, 80], drug repo-
sitioning [81, 82, 83, 84], and providing insights into molecular mechanisms
of drug actions and side effects [85, 86].
2.2. Graph theory for network analysis
2.2.1. Graph theoretic terminology
Theoretical insights from graph theory have been successfully applied to
various biological network modelling and analysis tasks (e.g., [87, 5, 67,
6, 78, 88]). In graph theory, a network or a graph is usually denoted by
G(V,E), where V is a set of n (or |V |) nodes and E ⊆ V × V is a set of m
(or |E|) edges connecting them. Nodes adjacent to a node v are called v’s
neighbours, and the number of edges connecting v is called v’s degree.
A path between two nodes u and v in a network is a sequence of edges
connecting them. A graph is said to be connected if there exists a path
between every pair of its nodes. The distance of nodes u and v, denoted by
d(u, v), is defined as the length (i.e., the number of edges) of the shortest
path between nodes u and v.
A graph is undirected if its edges have no direction; otherwise, it is
directed. A graph can be either weighted or unweighted depending on
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whether there is a weight assigned to each of its edges. A graph is bipartite
if its nodes V can be partitioned into two disjoint sets such that in each set,
the nodes belonging to it are not connected. For an undirected graph, if it
has no self-loops (i.e., edges connected at both ends to the same node) and
multiple edges (i.e., more than one edge between any two different nodes),
it is said to be a simple graph.
A subgraph S of a graph G is a graph whose nodes and edges belong to G.
A subgraph S of a graph G is induced if S contains all edges that appear in
G over the same subset of nodes. Given two graphs G(V,E) and G′(V ′, E′),
they are isomorphic if there is a bijective function f : V 7→ V ′, such that
for all u, v ∈ V , {u, v} ∈ E ⇔ {f(u), f(v)} ∈ E′.
In practice, different data structures can be used for the representation of
graphs. Three most commonly used representations are edge list, adjacency
list and adjacency matrix (Figure 2.3). An edge list of a graph G is simply
the list of G’s edges. An adjacency matrix of G is an n×n matrix, in which
an entry aij indicates the presence or absence of an edge between nodes i
and j. An adjacency list is an array of n lists, and a list i in the array
contains all neighbours of the node i. Generally speaking, an edge list or
an adjacency list is preferred to represent sparse graphs, and an adjacency
matrix is preferred to represent dense graphs.
2.2.2. Network comparison
One of the major challenges in biological network research is network com-
parison. It aims to identify similarities and differences between networks.
The comparison can be between two data networks (i.e., networks that rep-
resent data) or between a data network and a theoretical model (see Section
2.2.3 for details of network models). Network comparison is an essential
part of biological network analysis. However, since it relies on the subgraph
isomorphism problem, comparing large networks is computationally inten-
sive. The subgraph isomorphism problem is a computational task to identify
whether there is a subgraph S of a graph G that is isomorphic to another
graph H, and it has been proved that this problem is NP-complete [89].
For this reason, some computable approximate measures of network topol-
ogy, commonly called network properties, have been used to compare large
networks. Network properties can be roughly divided into two categories:
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Figure 2.3.: An example of a graph and its adjacency matrix, adjacency list
and edge list representations.
global network properties and local network properties.
Global network properties
Global network properties are statistical measures that describe an overview
of a given network. The most commonly used global network properties
include edge density, degree distribution, average diameter, and clustering
coefficient.
The edge density of a network is defined as the proportion of the number of
edges to the maximum possible number of edges. For a given networkG with
n nodes and m edges, the maximum number of edges is
(
n
2
)
= n(n − 1)/2,
thus its edge density is m/
(
n
2
)
. The degree distribution is the probability
distribution of nodes’ degrees over the whole network. Thus if nk denotes
the number of nodes in the network G with degree k, the degree distribution
of G is P (k) = nk/n, for each value of k. The average diameter (or average
path length) of a network is defined as the average distance over all pairs of
nodes in a network.
The clustering coefficient of a node is defined as the proportion of the
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number of edges between that node’s neighbours to the maximum possible
number of edges between the neighbours. Let deg(u) be the degree of a node
u and Eu be the number of edges between u’s neighbours, thus the clustering
coefficient of u is Cu = Ei/
(
deg(u)
2
)
. The average clustering coefficient of a
network is defined as the average of clustering coefficients over all nodes in
the network [90]. The distribution of average clustering coefficients of all
nodes with degree k in a network is called the clustering spectrum of the
network.
Global network properties of real-world networks have been extensively
studied as they are relatively easy to compute. For example, it has been
shown that many real-world networks have degree distributions that ap-
proximately follow power law distributions (so called scale-free [91, 92], also
see Section 2.2.3 for details). Meanwhile, many large real-world networks
tend to have small diameters and large clustering coefficients (so called
small-world [90]). However, these global network properties can not pre-
cisely describe a network’s topology. In particular, networks with exactly
the same value of a network property can have very different structures.
For example, a network with 3 triangles and a network with a 9-node circle
have the same number of nodes, the same number of edges and the same
degree distribution, but obviously these two networks have very different
structures (this example was illustrated in [47]). Furthermore, due to the
incompleteness and the sampling and data collection biases in current bio-
logical data, global network properties of biological networks may even be
misleading (discussed in Section 2.1). Therefore, it is essential to perform
local statistics for large biological networks.
Local network properties
Local network properties measure local structures of a network. There are
mainly two types of local network properties, network motifs and graphlets.
Network motifs are defined as subgraphs that recur in a data network sig-
nificantly more often than in randomised networks [61, 87]. Graphlets are
defined as small, connected and induced subgraphs of a larger network [5].
Both network motifs and graphlets can be considered as small building
blocks of large, complex networks, and have been successfully applied to
various network analysis tasks [61, 87, 5, 6, 46]. For example, Milo et al.
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Figure 2.4.: All 13 types of 3-node connected subgraphs. This figure is re-
produced from [61].
(2002) [61] identified network motifs in several real-world networks, includ-
ing transcriptional regulation network, food webs, neuron connectivity net-
work, electronic circuits network and World Wide Web, by scanning for all
possible 3-node and 4-node subgraphs (see Figure 2.4 for examples of 3-node
subgraphs). They showed that different types of networks had different mo-
tif sets, and thus suggested that network motifs could be used to classify
networks. Moreover, Shen-Orr et al. (2002) [87] showed that network motifs
of a transcriptional regulation network had specific biological functions, for
example, the feed-forward loop motif represented the response of external
signal of a system.
Network motifs have been used to compare the local structure of complex
networks [93, 94, 95]. An approach based on significance profile was pro-
posed by Milo et al. (2004) [93] for network comparison. To compute the
significance profile of a given network, Milo et al. first generated a set of ran-
domised networks with the same degree distribution as the given network,
then compared the given network with randomised networks according to
the occurrence of 3-node and 4-node subgraphs in these networks. For each
subgraph i, the statistical significance was computed by a Z score:
Zi = (Nreali − 〈Nrandi〉)/std(Nrandi), (2.1)
where Nreali is the frequency of the subgraph i appears in the given network,
and 〈Nrandi〉 and std(Nrandi) are the mean and the standard deviation of
the frequency of i appears in randomised networks. The significance profile
for the given network was defined as a vector of normalised Z score, SPi =
Zi/(
∑
Z2i )
1/2. By using this method, Milo et al. computed significance
profiles for different types of networks, and showed that several previously
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unrelated networks (such as a mammalian cell signalling network and a
neuronal synaptic network of Caenorhabditis elegans) were topologically
similar [93].
However, it has been noticed that motif-based approaches may lead to
wrong results, since the detection of network motifs highly depends on the
choice of the underlying null model [94]. For example, if the Erdo¨s-Re´ny
(ER) random graph (see Section 2.2.3 for details) is chosen as the null model,
it is very likely that dense subgraphs would be identified as network motifs
since they rarely occur in an ER random graph. Systematic approaches
based on another local network properties, graphlets, are free from the biases
introduced by null model selection. Details of graphlets and graphlet-based
approaches are discussed in Section 2.2.4.
2.2.3. Network models
Network models provide us a way to describe the structural features of a
system. With a precise mathematical model representing the structure of
biological networks, one can not only reproduce the observed biological data,
but also predict the system’s behaviour to gain novel insights.
One of the first steps in modelling biological systems is to develop math-
ematical models that have similar statistical properties to the real-world
networks. Several network models have been proposed for this purpose, in-
cluding Erdo¨s-Re´ny (ER) random graph [96, 97], ER random graph with
the same degree distribution as a data network (ER-DD), scale-free (SF)
network [91, 98], geometric random graph (GEO) [99], geometric gene du-
plication and mutation (GEO-GD) model [8] and stickiness index-based
(STICKY) network model [7]. These network models have been proved use-
ful in identifying network motifs [61, 87, 93], finding cost-effective strategies
for interactome detection [100], and predicting PPIs [101].
The ER model (Figure 2.5a) is one of the earliest network models. It
can be generated by fixing the number of nodes n in the network, and
adding edges uniformly at random until a given edge density is reached. If
the probability of adding an edge between any pair of nodes is ρ (i.e., ρ is
the edge density), an ER model created by this process has approximately
n(n − 1)ρ/2 edges. Despite the simplicity of the model, the ER model is
considered as one of the standard models to compare the data with, as many
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Figure 2.5.: Examples of model networks. Left: An ER model. Center: An
SF model. Right: A GEO model. Figures are taken from [47].
of its properties have been proven theoretically [102].
The degree distribution P (k) (i.e., P(k) is the fraction of nodes in the
network having degree k, see Section 2.2.1) of an ER model follows a bino-
mial distribution P (k) =
(
n−1
k
)
ρk(1− ρ)n−1−k. This distribution becomes a
Poisson distribution P (k) = (np)ke−np/k! in the limit of large n. However,
most real-world networks have degree distributions very different from this
[91, 92]. An ER-DD model is a variation of the ER model, in which the de-
gree distribution is forced to be the same as that of a data network. ER-DD
models can be generated by assigning ‘stubs’ to each node in the network
according to the degree distribution of the data network, and adding edges
to pairs of stubs at random (see [103] for details). The ER-DD model pre-
serves the degree distribution of the data network, while other properties
such as clustering coefficient are still the same as the ER model.
An SF model (Figure 2.5b) is a network model in which the degree distri-
bution follows a power law distribution P (k) ∼ k−γ , where γ is a parameter
typically in the range γ ∈ (2, 3) [91]. Many real-world networks, including
PPI networks, metabolic networks, World Wide Web networks and social
networks, have been conjectured to follow power law distributions [92]. An
SF model can be generated by a preferential attachment process proposed
by Baraba´si and Albert (1999) (so called SF-BA model) [91]. Starting with
an initial connected network, new nodes are added to the network and con-
nected to existing nodes with a probability that is proportional to the degree
of existing nodes until a given density is reached. As a result of this pro-
cess, the degree of a few nodes (hubs) is significantly higher than that of
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the other nodes, as illustrated in Figure 2.5a. An SF model can also be
generated based on a gene duplication and mutation model (SF-GD) [98].
In the duplication step, a parent node is chosen uniformly at random from
the existing network and a new child node that connects to all neighbours
of the parent node is added. An edge between the parent node and the child
node is added with a given probability p. In the mutation step, for each
node that connects to both the parent node and the child node, one of the
two edges is removed with a given probability q. If the degree distribution
of the data network follows a power law distribution, an ER-DD model gen-
erated from the data network is also an SF model. This is a special case of
an ER-DD model called random SF (SF-RND).
SF models have small average diameters and power law degree distri-
butions similar to that of the real-world networks, and they were used to
model early PPI networks of Saccharomyces cerevisiae (yeast) [104, 105].
However, it was argued that the power law degree distribution in these PPI
networks was an artifact of sampling: these early PPI networks were largely
incomplete, thus the observed scale free topology could not be confidently
extrapolated to complete interactomes [52]. Evidences have shown that
PPI networks can be better modelled by other models, in particular, GEO
models, than SF models [5, 6].
In a GEO model (Figure 2.5c), nodes represent uniformly randomly dis-
tributed points in a metric space, and nodes are connected by edges if the
distance of their corresponding points is within some radius threshold r [99].
A GEO model has a degree distribution that follows a Poisson distribution,
which is different from the real-world networks. However, GEO models
reproduce high clustering coefficients and small average diameters of real-
world networks, and have been shown to provide better fit to the currently
available PPI networks than ER and SF models [6]. GEO-GD models are
GEO models that incorporate the principles of gene duplications and mu-
tations [8]. To generate a GEO-GD model, one chooses a parent node from
the existing network uniformly at random, and adds a child node in a ran-
dom direction at a randomly chosen distance either up to r with probability
p or up to 10r with probability 1 − p (see [8] for more details). GEO-GD
models have degree distributions that follow power law distributions, small
average diameters and high clustering coefficients, thus they preserve the
global properties of the real-world networks.
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Degree distribution Clustering coefficient AVG diameter
Real-world Power law High Small
ER Poisson Low Small
ER-DD Power law Low Small
SF Power law Low Small
GEO Poisson High Small
GEO-GD Power law High Small
STICKY Power law High Small
Table 2.1.: Comparison between different network models based on global
network properties.
A STICKY model is based on a stickiness index that is proportional to
the degree of a node in a real network [7]. This model was proposed partic-
ularly for modelling PPI network, under the assumption that the higher the
degrees of two proteins in the PPI network, the more likely they interact
with each other. The STICKY model also preserves the global properties
of the real-world networks, and it has been shown that currently available
PPI networks are well-fit by the STICKY model [7, 106].
Table 2.1 summaries a comparison between different network models
based on their global network properties. Since real-world networks are
shown to be small-world and scale-free, they have small average diameters,
high clustering coefficients, and power law degree distributions. In this re-
gard, real-world networks seem to be better fit by GEO-GD and STICKY
models than other models.
2.2.4. Graphlet-based measures for network analysis
Systematic approaches based on graphlets have been introduced to measure
the structure (or topology) of large networks. As described in Section 2.2.2,
a graphlet is defined as a small, connected and induced subgraph of a larger
network [5]. Figure 2.6 depicts all 30 of the possible graphlets that have 2,
3, 4, and 5 nodes. Topologically identical nodes within a graphlet are said
to belong to the same automorphism orbit [6]. In total there are 73 different
automorphism orbits in the 30 graphlets, as shown in Figure 2.6.
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Figure 2.6.: Graphlets with 2-5 nodes G0,G1, ..., G29. The automorphism
orbits are numbered from 0 to 72, and the nodes belonging to
the same orbit are of the same shade within a graphlet [6].
RGF distance and GDD agreement
Graphlets have been used to measure the similarity of the topology of PPI
networks and network models [5, 6]. In particular, two measures have been
proposed for this purpose. One is based on comparing graphlet frequencies
between two networks, and is termed relative graphlet frequency (RGF)
distance [5]. The other is based on comparing graphlet degree distributions
(GDDs) between two networks, and is termed GDD agreement [6]. Both
measures allow quantification of the similarity between the topology of two
data networks, or comparison of a data network with a network model.
The RGF distance between two networks G and H is computed as follows.
Let Ni(G) be the number of graphlets of type i (i ∈ 1, ..., 29) in the network
G. The relative frequency of graphlets of type i is defined as Ni(G)/T (G),
where T (G) =
∑29
i=1Ni(G) is the total number of graphlets of G. The RGF
distance between two networks G and H is computed as:
RGF (G,H) =
29∑
i=1
|Fi(G)− Fi(H)|, (2.2)
where Fi(G) = − log(Ni(G)/T (G)). This measure has been applied to ex-
amine the fit of ER, ER-DD, SF-BA, and GEO models to PPI networks
of Saccharomyces cerevisiae (yeast) and Drosophila melanogaster (fruit fly)
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[5]. With respect to the measure, it has been shown that the topology of
PPI networks is better modelled by a GEO model than a SF-BA model [5].
GDD agreement was later introduced as another graphlet-based measure
for network comparison [6]. The notion of the degree has been generalised
to graphlet degree: the degree distribution over degrees k of a graph is a dis-
tribution of how many nodes have degree k; in turn, a GDD is an analogous
distribution for an automorphism orbit that counts the number of nodes
touching this orbit k times over all k. For example, the GDD corresponding
to orbit 3 in Figure 2.6 measures how many nodes touch k triangles for each
value of k. There are 73 GDDs for graphlets with up to 5 nodes, and the
degree distribution is the first one of them.
More specifically, let djG be the j
th GDD of a network G and djG(k) be the
number of nodes in a network G that are touched k times by a particular
automorphism orbit j shown in Figure 2.6. To compute the normalised
graphlet degree for orbit j, djG(k) is first scaled by 1/k to decrease the
contribution of larger degrees in a GDD, and then normalised to give a
total sum of 1,
N jG(k) =
djG(k)/k∑∞
l=1 d
j
G(l)/l
. (2.3)
For two networks G and H and a particular orbit j, the distance Dj(G,H)
between their normalised jth GDD is defined as:
Dj(G,H) =
1√
2
(
∞∑
k=1
[N jG(k)−N jH(k)]2)
1
2 , (2.4)
where the 1/
√
2 is a normalisation constant that ensures the distance is
always less than 1. Finally, the GDD agreement between networks G and
H is defined as:
GDDA(G,H) =
1
73
72∑
j=0
(1−Dj(G,H)). (2.5)
If two networks G and H have a GDD agreement close to 1, that means
G and H are considered to be topologically similar as their GDDs, scaled
appropriately to their network size, are statistically similar. GDD agreement
has been used to compare 14 PPI networks of eukaryotic organisms with 4
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random network models, and the fit between the PPI networks and the
model networks has been assessed [6].
Graphlet signature similarity
Graphlet-based measures have also been developed to measure the topologi-
cal similarity between nodes in a network. The graphlet signature similarity
compares nodes in a network based on the local structure of node neighbour-
hoods [46]. The graphlet signature is a generalisation of the notion of the
degree: the degree of a node u counts how many edges it touches; in turn,
the graphlet signature of u is a 73-dimensional vector that counts how many
times u is touched by each of the automorphism orbits shown in Figure 2.6
[46].
The graphlet signature similarity of a pair of nodes u and v is computed
as follows. Let ui be the i
th element of the graphlet signature of u, i.e., ui
is the number of times u is touched by the particular automorphism orbit
i. Then the distance between the ith orbit of nodes u and v is defined as:
SigDisti(u, v) = wi × | log(ui + 1)− log(vi + 1)|
log(max(ui, vi)) + 2
. (2.6)
where wi is a weight assigned to orbit i which is defined as wi = 1 −
log(oi)/ log(73), and oi is the dependency count of orbit i. For example,
for orbit 4, its dependency count o4 is 3, as orbit 15 is affected by orbits 0,
1, and itself (see [46] for details). Finally, the graphlet signature similarity
between u and v is computed as:
SigSim(u, v) = 1− 1∑72
i=0wi
(
72∑
i=0
SigDisti(u, v)) (2.7)
Signature similarities have been applied to measure the topological sim-
ilarities between proteins in a PPI network [46]. It has been shown that
topologically similar proteins are very likely to belong to the same protein
complexes, perform the same biological functions, be localised in the same
subcellular compartments, and have the same tissue expressions [46]. Fur-
thermore, topological similarities of proteins in a PPI network have been
considered as a complementary information to sequence similarities, and
have been applied to detect homologous proteins [46], align PPI networks
of different species [9, 10, 11, 12], uncover melanogenesis regulatory network
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components, and identify disease genes [40, 107].
Graphlets for network alignment
Graphlet-based measures discussed above have also been applied for many
biological network alignment tasks [9, 10, 11, 12, 108]. Given two or more
networks of the same type, network alignment allows us to compare net-
works and identify conserved subnetworks within them. For example, net-
work alignment can be used to measure the global similarity between PPI
networks of different species, further to infer phylogenetic relationships [11].
Such alignment could also provide transfer of knowledge between species,
as well as insights into evolution, disease and gene function [47].
Analogous to sequence alignment, network alignment can be local or
global. Local network alignment algorithms, such as the BLAST family
(PathBLAST [109], NetworkBLAST [110] and NetworkBLAST-M [111]),
MAWISH [112], NetAlign [113] and Graemlin 1.0 [114], aim to match sub-
networks from one network to subnetworks in another network. However,
the alignments produced by these algorithms may be ambiguous, as local
alignment algorithms map each subnetwork of similarity independently, thus
allow one node to have different pairings. Global network alignment algo-
rithms uniquely map each node in one network (the smaller network) to
exactly one node in the other network (the larger network), even though
this may lead to suboptimal matchings in some local regions. These global
network alignment algorithms include the IsoRank family (pairwise Iso-
Rank [115], multiple IsoRank [116] and IsoRankN [117]), Graemlin 2.0
[118], GA and PATH [119], HopeMap [120], NATALIE [121, 122], PISwap
[123], GEDEVO [124], SPINAL [125], NETAL [126] and graphlet-based net-
work alignment algorithms [9, 10, 11, 12]. So far four graphlet-based algo-
rithms have been proposed for global network alignment, including GRAph
ALigner (GRAAL) [9], Hungarian-algorithm-based GRAAL (H-GRAAL)
[10], Matching-based Integrative GRAAL (MI-GRAAL) [11] and Common-
neighbors-based global GRAAL (C-GRAAL) [12]. These graphlet-based
algorithms align two networks by considering the graphlet signature similar-
ities of network nodes. Graphlet signature similarity has also been extended
for fast and flexible alignment of protein 3D structures [108].
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Software for graphlet-based measures: GraphCrunch
Several graphlet-based measures, including RGF distance, GDD agreement,
signature similarity, and the GRAAL network alignment algorithm, have
been implemented in the open source software GraphCrunch [127, 128]. In
addition, GraphCrunch also contains random network generators of ER, ER-
DD, GEO, SF-BA, GEO-GD, SF-GD and STICKY models. GraphCrunch
can be used to solve many network analysis and modelling tasks, such as
finding the best fitting model for a given network, comparing different net-
works based on their global and local network properties, aligning two
networks using GRAAL (see [9] for details of network alignment and the
GRAAL algorithm), as well as identifying clusters in a given network based
solely on network topology.
2.3. Disease-disease associations
2.3.1. Disease classification
Diseases can be classified based on different criteria. Two of the most widely
used criteria are topography and anatomy. In the topographic classification,
diseases are classified based on the affected region or system (e.g., gastroin-
testinal disease and vascular disease), while in the anatomic classification,
diseases are classified based on the affected organ or tissue (e.g., heart dis-
ease and liver disease). Other criteria such as physiology, pathology, etiology
and epidemiology, can also be used to classify diseases.
Published and maintained by the World Health Organization (WHO),
the ICD classification system is considered to be the international standard
of disease classification [1]. It provides a system of diagnosis codes for
identifying and grouping diseases, and has been used worldwide for general
epidemiological and health management purposes. In the ICD classification
system, diseases are classified into several major categories (see Table A.1),
which can be further divided in subgroups represented by 3-5 digit level
diagnosis codes. For example, according to the 9th revision of ICD (ICD-9)1,
diabetes mellitus (ICD-9 code: 250) is classified under the major category
‘endocrine, nutritional and metabolic diseases, and immunity disorders’, and
it can be further divided into subgroups represented by 4-digit level codes
1http://www.who.int/classifications/icd/en/
39
(e.g., ICD-9 code 250.1 for diabetes with ketoacidosis) or 5-digit level codes
(e.g., ICD-9 code 250.10 for type 2 diabetes with ketoacidosis).
Another commonly used disease classification is the MeSH thesaurus, a
controlled vocabulary produced by the National Library of Medicine (NLM)
[2]. The MeSH thesaurus is used by the NLM for indexing, cataloging,
and searching for biomedical and health-related information and documents
collected in databases such as the PubMED2. It consists of sets of terms that
are arranged in a 12-level hierarchical tree structure3. As shown in Table
A.2, the most general level of the MeSH tree contains broad headings such
as ‘Neoplasms’ (MeSH tree ID: C04) and ‘Mental Disorders’ (MeSH tree
ID: F03). More specific headings can be found at more narrow levels of
the MeSH tree, such as ‘Inflammatory Breast Neoplasms’ (MeSH tree ID:
C04.588.180.576).
Since there exist different disease classification systems, the Disease On-
tology4 (DO) has been developed recently with the aim to provide a unifying
representation of human diseases for the biomedical community [129]. It also
contains cross mappings between several common biomedical vocabularies
including ICD, MeSH, OMIM, SNOMED and UMLS. Such mappings are
essential for integrating disease-related data obtained from different sources
such as GWAS studies, patient records and the literature.
2.3.2. Computational approaches for uncovering
disease-disease associations
During the past decade, various large-scale genomic, proteomic, transcrip-
tomic and metabolomic studies have provided an abundance of biological
data describing diseases, prompting the scientific community to gain in-
sights into diseases and their relationships at a molecular systems-level. As
a result, several computational approaches have been developed and applied
to uncover disease-disease associations from various types of biological data.
Text mining is one of the most commonly used methods to uncover phe-
notype associations. van Driel et al. (2006) [65] inferred similarities between
human phenotypes by an automated text mining of the OMIM database,
and found those similarities were positively correlated with a number of mea-
2http://www.ncbi.nlm.nih.gov/pubmed
3http://www.nlm.nih.gov/mesh/trees.html
4http://disease-ontology.org
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sures of gene function. Phenotype associations identified by van Driel et al.
(2006) were further used to investigate the modularity of phenotypes and its
correlation with disease classification, functional genomics and drug-target
associations by Jiang et al. (2008) [130]. Also by text mining the OMIM
database, Lage et al. (2007) [66] derived phenotype similarity scores and
integrated them with human PPI data to predict disease gene candidates.
A recent study by Xu et al. (2013) [131] extracted disease-manifestation
relationships by text mining the literature and inferred disease-disease as-
sociations based on manifestation similarities.
Apart from large-scale disease-gene association databases like OMIM,
other resources such as electronic patient records have also been used for
studying disease-disease associations. A type of disease-disease association
that can be derived from medical records is disease comorbidity, which indi-
cates the potential for the co-occurrence of diseases in the same individual.
Hidalgo et al. (2009) [132] built a phenotypic database summarising co-
morbidity data obtained from the disease history of 32 million American
patients. Two statistical measures were used to quantify the strength of co-
morbidity association between a pair of diseases: the Relative Risk (RR) and
φ-correlation. They showed that both measures captured statistically sig-
nificant comorbidity associations, but RR tended to prioritise associations
between diseases within the same ICD-9 category while φ-correlation tended
to prioritise associations between diseases across different ICD-9 categories.
This phenotypic database was further analysed to examine the correlation
between comorbidity and disease progression [132], the underlying structure
of cellular networks [133] and the evolution of human disease genes [134].
Comorbidity associations between diseases have also been used to infer ge-
netic overlaps between phenotypes [135] and investigate possible molecular
basis for diseases [136].
Disease-disease associations have also been inferred by other computa-
tional approaches, including analysing disease-associated SNPs from GWAS
data [137, 138], fusing systems-level molecular data [139], measuring the
correlation between disease-related gene expression data [81, 140] and com-
paring annotations in biomedical ontologies such as GO [141], DO [142]
and Human Phenotype Ontology (HPO) [143]. Recently, network-based
approaches have been successfully applied to represent and analyse the in-
terconnectedness of human diseases. Goh et al. (2007) [67] constructed
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Figure 2.7.: An example of how to construct the human disease network
(left) and the disease gene network (right) from the diseasome
bipartite network (center). The diseasome network was con-
structed from the disease-gene association data collected by
Goh et al. (2007) [67]. Only diseases classified as ‘Gastroin-
testinal diseases’ and their associated genes were shown in the
figure. Blue and orange nodes represent diseases and human
genes respectively. The size of a node is proportional to its
degree in the diseasome network.
.
the first human diseasome, a bipartite network representing disease-gene
associations obtained from OMIM (discussed in Section 2.1.3). They also
generated two network projections: one was the ‘human disease network’,
in which nodes were diseases and two diseases were connected by an edge
if they shared at least one gene; the other was the ‘disease gene network’,
in which nodes were genes and two genes were connected by an edge if they
were involved with the same disease. Figure 2.7 demonstrates the construc-
tion of the human diseasome and its two projections. By analysing these
networks with a human PPI network, Goh et al. (2007) showed that genes
associated with the same disease were functionally related, and the majority
of disease genes were nonessential and showed no tendency to encode ‘hubs’
in the PPI network.
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A human disease association network can also be constructed based on
other systems-level data [144, 57, 140, 145]. For example, Lee et al. (2008)
[144] used metabolic data along with OMIM to construct a metabolic disease
network in which two diseases were connected if their associated enzymes
catalysed adjacent metabolic reactions; Li and Agarwal (2009) [57] associ-
ated diseases to biological pathways where disease genes were enriched, and
constructed a pathway-based disease network by connecting diseases that
shared at least one pathway. Analysis of human disease networks have been
shown useful for building novel hypotheses about disease mechanisms and
identifying new drug targets and biomarkers for complex diseases [41].
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3. Evaluation of graphlet-based
measures
Gaining biological insights from PPI networks requires the development of
efficient and biologically meaningful algorithms for their analysis. System-
atic measures based on graphlets are proving useful in this regard. Recently,
the use of graphlet-based measures for biological network comparison has
been questioned: it has been claimed that the measures are ‘unstable’ in
regions of low edge density.
In this chapter, we demonstrate that graphlet-based measures are suit-
able for biological network comparison. Starting by generating empirical
distributions of GDD agreement scores, we identify the edge density re-
gions in which the topology of model networks is ‘unstable’, and show how
graphlet-based measures correctly detect this topological instability. We
also demonstrate that this ‘instability’ does not affect the analysis of re-
cent PPI networks. Furthermore, we show that data networks have local
densities much higher than a model network would have, since models are
uniformly dense. Hence, graphlet-based measures are stable in regions that
are of interest in real networks. Finally, we validate the use of graphlet-
based measures for finding well-fitting network models for PPI networks by
using a recently devised non-parametric statistical test. We show for the
first time that five viral species, possessing the latest and most complete
PPI networks, are well-fit by several network models.
The work presented in this chapter is in collaboration with Prof. Wayne
Hayes and it is published in the following paper:
• W. Hayes, K. Sun, and N. Przˇulj, “Graphlet-based measures are suit-
able for biological network comparison,” Bioinformatics, vol. 29, no.
4, pp. 483-491, 2013.
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3.1. Motivation
Networks have been used to represent interactions in molecular biology,
such as those between genes in gene regulatory networks and those be-
tween proteins in PPI networks (discussed in Section 2.1). A PPI network
models physical interactions between proteins in a cell, where a node rep-
resents a protein and an undirected edge exists between two nodes if the
corresponding proteins can physically bind to each other. The whole set of
such interactions in an organism forms the interactome. Understanding the
structure of PPI networks is an integral step towards understanding cellular
systems.
Recent advances in high-throughput PPI detection methods, such as Y2H
screening [15, 16, 18, 19, 20, 21] and MS of purified complexes [22, 23, 25, 24]
have provided an abundance of network data. As these PPI networks are
large and complex, it is necessary to develop efficient and biologically mean-
ingful algorithms for their analysis. Since exactly solving many network
analysis problems (e.g., network comparison) is computationally intractable,
computable approximate measures have been developed to analyse these
networks (discussed in Section 2.2.2).
Systematic measures based on graphlets have been introduced to analyse
the topology of large networks [5, 6]. In particular, two measures have been
proposed for network comparison, namely RGF distance and GDD agree-
ment. RGF distance is based on comparing graphlet frequencies between
two networks [5], while GDD agreement is based on comparing graphlet de-
gree distributions (GDDs) between two networks [6]. Both measures allow
quantification of the similarity between the topology of two data networks,
or comparison of a data network to a model network. For example, GDD
agreement has been used to compare fourteen PPI networks of eukaryotic
organisms with four different random network models, and assess the fit
between PPI networks and model networks [6]. Details of RGF distance
and GDD agreement can be found in Section 2.2.4.
Recently, the use of graphlet-based measures for network comparison has
been questioned: it has been claimed that the measures are ‘unstable’ in
regions of low edge density [13]. In the study of Rito et al. (2010) [13], em-
pirical distributions of GDD agreement scores were calculated and a novel
non-parametric test for assessing the statistical significance of the fit be-
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tween PPI networks and theoretical models was introduced. Six PPI net-
works of yeast and human were tested, and it was found that none of these
PPI networks were well-fit by the three random network models tested, i.e.,
ER, ER-DD, and GEO models [13].
In the rest of this chapter, we first give details of PPI networks we anal-
ysed, along with methods we used to model and analyse these PPI networks.
We then demonstrate graphlet-based measures are suitable for biological
network comparison, based on the following observations. First, RGF dis-
tance and GDD agreement are not ‘unstable’ for low edge density networks;
instead, they correctly detect instability that is present in the structure of
low edge density model networks. Second, the ‘unstable’ low-density region
described in Rito et al. (2010) [13] is small in large networks, and cur-
rent PPI networks have densities outside this region. Third, PPI networks
used in Rito et al. (2010) [13] are not only out-of-date now, but were also
out-of-date at the time of their study. Fourth, local densities of natural
networks are much higher than those of model networks, since models are
uniformly dense. Finally, we use the non-parametric test proposed in Rito
et al. (2010) [13] to demonstrate that PPI networks of many species, par-
ticularly five viral species, are well-fit by several existing network models.
3.2. Methods
3.2.1. Data: PPI networks
We collected and analysed eighteen PPI networks of various species, includ-
ing five PPI networks of herpesvirus, four PPI networks of prokaryotes and
nine PPI networks of five eukaryotes (Table 3.1).
Viral PPI networks were collected from Fossum et al. (2009) [26], includ-
ing PPI networks of herpes simplex virus type 1 (HSV-1), Kaposi’s sarcoma-
associated herpesvirus (KSHV), varicella-zoster virus (VZV), Epstein-Barr
virus (EBV) and murine cytomegalovirus (mCMV). These viral PPI net-
works are considered to be the most complete PPI networks, as they were
produced by complete genome-wide Y2H experiments, which means all pos-
sible pairs of proteins were tested for interaction.
The four PPI networks of prokaryotes we used are bacterial PPI net-
works collected from different studies, including PPI networks of Campy-
46
PPI Nodes Edges Density Reference
HSV-1 47 100 0.09251 Fossum et al. (2009) [26]
KSHV 50 115 0.09388 Fossum et al. (2009) [26]
VZV 57 160 0.10025 Fossum et al. (2009) [26]
EBV 60 208 0.11751 Fossum et al. (2009) [26]
mCMV 111 393 0.06437 Fossum et al. (2009) [26]
CJJ 1,111 2,988 0.00485 Parrish et al. (2007) [146]
HS 1,529 2,667 0.00228 Stelzl et al. (2005) [18]
MZL 1,804 3,094 0.00190 Shimoda et al. (2008) [147]
HG 1,873 3,463 0.00198 Rual et al. (2005) [19]
SPP 1,920 3,102 0.00168 Sato et al. (2007) [148]
ECL 1,941 3,989 0.00212 Peregrin-Alvarez et al. (2009)
[27]
AT 2,634 5,529 0.00159 Arabidopsis Interactome
Mapping Consortium (2011)
[21]
WB 2,817 4,527 0.00114 BioGRID (ver. 3.1.74) [30]
YB 5,607 57,143 0.00364 BioGRID (ver. 3.1.74) [30]
FB 7,372 24,063 0.00089 BioGRID (ver. 3.1.74) [30]
HB 8,920 35,386 0.00089 BioGRID (ver. 3.1.74) [30]
HR 9,141 41,456 0.00099 Radivojac et al. (2008) [149]
HH 9,465 37,039 0.00082 HPRD (ver. 9) [150]
Table 3.1.: The eighteen PPI networks we analysed, ordered by size.
lobacter jejuni (CJJ) [146], Mesorhizobium loti (MZL) [147], Synechocystis
sp. PCC6803 (SPP) [148] and Escherichia coli (ECL) [27]. SPP and MZL
were both constructed from PPIs produced by Y2H experiments [148, 147].
CJJ is the high confident part of the PPI network of C. jejuni produced
by Y2H experiments [146]. ECL is the high confident functional interaction
network of E.coli inferred from both experimental interaction datasets and
computational predication datasets [27].
We also analysed nine PPI network of five eukaryotes, including Ara-
bidopsis thaliana, Saccharomyces cerevisiae (yeast), Caenorhabditis elegans
(nematode worm), Drosophila melanogaster (fruit fly), and Homo sapiens
(human). As can be seen from Table 3.1, HS was constructed by using the
human PPIs reported by Stelzl et al. (2005) [18], and HG was constructed
by using the human PPIs reported by Rual et al. (2005) [19]. Since Stelzl
et al. (2005) [18] and Rual et al. (2005) are the first Y2H studies of the
human interactome, both HS and HG are largely incomplete. Note that
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these two PPI networks were analysed both by Przulj (2007) [6] and Rito
et al. (2010) [13]. HH is the human PPI network obtained from HPRD
version 9 [150] (released in April 2010). HR is the human PPI network
constructed by Radivojac et al. (2008) [149]. Finally, HB, WB, FB and YB
are PPI networks of human, nematode worm, fruit fly and yeast obtained
from BioGRID version 3.1.74, released in March 2011 [30]. The PPI net-
work of Arabidopsis (AT) was constructed by using PPIs published by the
Arabidopsis Interactome Mapping Consortium (2011) [21].
Note that for all PPI networks, we removed self-loops, duplicate interac-
tions and inter species interactions from the PPI data, as we model these
PPI data as simple, undirected networks (discussed in Section 2.1.1 and
Section 2.2.1).
3.2.2. Network models and their utility
Random network models discussed in this chapter include ER, ER-DD (SF-
RND), GEO, GEO-GD, SF-GD and STICKY models. Details of these
network models and their properties can be found in Section 2.2.3. Models
play a key role in understanding the behaviour of complex systems. A pre-
cise model that represents the structural features of a system can provide us
with a way to describe the observed data, and more importantly, it allows
us to predict the system’s behaviour to gain novel insights. Thus, modelling
biological networks is fundamental to understanding complex biological sys-
tems.
One of the first steps in modelling biological networks is to develop math-
ematical models that have similar statistical properties to the real-world
networks. However, current biological networks are noisy and largely in-
complete (discussed in Section 2.1). In addition, they contain sampling
biases as well as other biases in data collection, handling and interpretation
[151, 152, 52, 153, 53]. Thus, due to the noise, incompleteness and biases
in the data, it is very difficult to find the model that perfectly fit the data.
Instead, our goal is to find the model that better fit the data to guide the
development of network models in the right direction.
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(a) ER model (b) GEO model
Figure 3.1.: GDD agreement scores vs. edge density when comparing (a) 50
ER model networks to each other, (b) 50 GEO model networks
to each other. Edge densities of the PPI networks analysed by
Rito et al. (2010) are indicated by bars on the top x-axis. These
PPI networks are discussed in Section 3.3.3. In (a), arrows along
the x-axis indicate the approximate edge density at which Rito
et al. (2010) expected the first graphlet to appear in an ER
model network with 500 nodes (indicated by short arrows) and
2000 nodes (indicated by long arrows). In (b), arrows along the
x-axis indicate the approximate edge density at which Rito et
al. (2010) expected 3-node graphlets to appear in a GEO model
network with 500, 1000 and 2000 nodes. These two figures are
taken from Rito et al. (2010) [13]. Note that two red lines are
added into the figures to indicate the ‘unstable’ regions of ER
and GEO model (will be discussed in Section 3.3.2).
3.3. Results and discussion
3.3.1. Sensitive vs. unstable
It has been concerned that graphlet-based measures are ‘unstable’ in regions
of low edge density [13]. In particular, Rito et al. (2010) [13] questioned
the use of GDD agreement (GDDA) for network comparison. They claimed
that ‘GDDA has a pronounced dependency on the number of edges and
vertices of the networks being considered’, and ‘GDDA score is not stable
in the region of graph density relevant to current PPI networks’ [13]. Their
arguments can be illustrated by Figure 3.1, which depicts the dependency of
GDD agreement scores on edge density (i.e., the proportion of the number
of edges to the maximum possible number of edges, discussed in Section
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Figure 3.2.: GDD agreement scores vs. edge density when comparing 30
random model networks to each other with (a) 50 nodes, (b)
100 nodes. Error bars are standard deviations of GDD agree-
ment scores. Since all models have about the same variance,
we show the error bars only for ER models for better visualisa-
tion. Green lines mark the edge densities of the five viral PPI
networks discussed in Section 3.2.1. In all cases, the viral PPI
networks have densities outside the region of sensitivity.
2.2.2) when comparing two model networks to each other. The abrupt drop
of GDD agreement curves at low edge density regions shown in these figures
was referred to as ‘unstable GDDA’ in Rito et al.’s study [13].
It is crucial to distinguish between a measure being unstable, versus
a measure being sensitive when the structure of a network is unstable
(i.e., network properties have a statistically high variance). We claim that
graphlet-based measures (both GDD agreement and RGF distance) are sen-
sitive that they correctly detect differences between the structure of various
networks. For example, consider two networks: one contains four isolated
edges and the other contains a square and four isolated nodes. Both net-
works have eight nodes and four edges, but obviously, their structures are
very different from each other. Both RGF distance and GDD agreement
would correctly detect this difference. Thus, it is not the measure that is
unstable, but the network structure itself is unstable at low edge density
regions. Graphlet-based measures correctly measure the topological insta-
bility in networks with a low edge density.
For this reason, we believe that the abrupt drop of GDD agreement curves
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Figure 3.3.: GDD agreement scores vs. edge density when comparing 30
GEO model networks to each other, with 500, 1000, 2000, 5000
and 10000 nodes. Similar plots that illustrate the sensitivity of
GDD agreement and RGF distance when comparing other ran-
dom model networks (ER, SR-RND, GEO-GD and STICKY)
can be found in Figure A.3. k1/n indicates the edge density
where the minimum model-vs-model GDD agreement score for
GEO models with 500 nodes occurs, and k2/n indicates the
edge density where the model-vs-model GDD agreement score
for GEO models with 500 nodes recovers.
at low edge densities is due to network properties having a statistically high
variance at low edge densities. This high variance is shown in Figure 3.2
and Figure 3.3, as the error bars which represent the standard deviations of
GDD agreement scores are obviously larger at low edge densities than they
are at high edge densities. The network’s topological instability causes a
low GDD agreement score when comparing two model networks that have
low edge densities. The network properties of model networks become more
similar at higher edge densities, resulting in a higher GDD agreement score
when comparing two networks generated from the same model.
Note that in Figure 3.2 and Figure 3.3, a point in a curve represents an
average GDD agreement score when comparing 30 random model networks
to each other. We chose 30 as the number of networks we used since a
sample size of 30 networks is more statistically significant than any smaller
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Figure 3.4.: GDD agreement is robust with respect to noise. In particular,
we see that adding, deleting, or re-wiring as many as 60% of
the edges in the model networks has little effect on which model
best fits the data. Thus, conclusions about which models better
fit the data are relatively insensitive to the fact that real-world
network data contain substantial amounts of noise.
values (e.g., 10 or 20 networks). Meanwhile, the shape of the curves does not
change with the increased number of model networks (see Figure A.1 in the
Appendix). Using a large sample size (e.g., 100 networks) is computationally
expensive and also unnecessary as demonstrated in Figure A.1.
GDD agreement is sensitive to noise, whereas conclusions about network
fit using GDD agreement are robust to noise (see Section 2.1 as well as
[5, 52, 152, 6, 101] for discussions of noise). Figure 3.4 shows how GDD
agreement scores change when we add, delete, and rewire up to 60% of
edges in the model networks. As can be seen, GDD agreement is sensitive
as it generally decreases with increasing noise level. For example, GDD
agreement between the yeast PPI network YB and an SF-GD model network
is about 0.86, while the score drops to 0.8 when we rewire 60% of edges
in the model network. Meanwhile, we can also observe from Figure 3.4
that the ordering of which model best fits the data undergoes only small
changes when noise is added. In particular, all curves in Figure 3.4 generally
have a decreasing tendency, indicating that the orderings of models on the
horizontal axis remains the same, independent of noise level.
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3.3.2. The size of the ‘unstable’ region
To examine whether the ‘unstable’ regions affect the analysis of current PPI
networks, we analysed eighteen PPI networks of various species (discussed
in Section 3.2.1). We found that even small real-world networks, such as
the viral PPI networks, have edge densities outside the topologically ‘un-
stable’ region. Figure 3.2 depicts the edge densities of viral PPI networks
(green vertical lines) and shows that they are outside the ‘unstable’ region,
regardless of the assumed theoretical model. A similar effect for larger PPI
networks is demonstrated in Figure 3.5 and Figure 3.6. In these two fig-
ures, we plot a surface depicting the dependency of GDD agreement on the
number of nodes n and the edge density ρ for ER and GEO models. The
non-viral PPI networks listed in Table 3.1 are plotted in the (n, ρ) plane
according to their sizes and edge densities. As can be seen from Figure 3.6,
none of these PPI networks are in the ‘unstable’ region of GEO models.
Only a few PPI networks (such as HS and HG, which are the earlies human
PPI networks) are in the ‘unstable’ regions of ER models (Figure 3.5). Note
that the size of the ‘unstable’ regions varies is not the same in different ran-
dom models. For example, the ‘unstable’ region of a GEO model is much
smaller than that of an ER model with the same number of nodes and edge
density. Furthermore, the ER model is the simplest random model and it
is well known that the structure of real PPI networks is very different from
that of an ER model (e.g.,[5, 6]; also discussed in Section 2.2.3).
In order to decide whether a given network has an edge density in the
‘unstable’ region, we need to quantify the size of the ‘unstable’ region for
model networks. As can be seen from Figure 3.1, it is clear that the range
of the ‘unstable’ region for ER models with 500 nodes is in [0, 0.01], and the
range of the ‘unstable’ region for GEO models with 500 nodes is in [0, 0.005].
From Figure 3.3 and Figure 3.1b, we can infer that the minimum GDD
agreement score for GEO-vs-GEO comparisons occurs at an edge density
that is proportional to k1/n for some value of k1, where n is the number of
nodes in the network. Furthermore, the ‘recovery’ of GDD agreement scores
referred by Rito et al. (2010) occurs at an edge density that is proportional
to k2/n for some value of k2 (k2 > k1) (see Figure 3.3 for an example of the
scaling for GEO models with 500 nodes). This scaling is also valid for all
other random models: as can be observed from Figure 3.2, the size of the
53
Figure 3.5.: Empirical distributions of GDD agreement for ER-vs-ER com-
parisons. The surface defined by 30x30 ER-vs-ER GDD agree-
ment scores as a function of number of nodes n and edge den-
sity ρ. Each line across the surface represents the (n, ρ) of a
real PPI network listed in Table 3.1. These PPI networks are
grouped according to the kingdom (e.g., Bacteria, Plantae and
Animalia) that the species belongs to, shown by lines with dif-
ferent colours.
Figure 3.6.: Empirical distributions of GDD agreement for GEO-vs-GEO
comparisons (see the legend of Figure 3.5 for details). As can
be seen, none of the PPI networks are in the ‘unstable’ region
of GEO models.
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‘unstable’ region for all models is doubled when we increase the number of
nodes from 50 to 100. Since the ‘unstable’ region for GEO models with 500
nodes spans the edge density region ρ ∈ [0, 0.005] (see Figure 3.3 and Figure
3.1b, we infer that k2 ≈ 2.5 for GEO models. Similarly, we infer that k2 ≈ 5
for ER models (see Figure 3.2 and Figure 3.1a). Generally speaking, it is
reasonable to hypothesise that the ‘unstable’ region spans the edge density
region ρ ∈ [0, k2/n] where the value of k2 depends on the network model
but is likely in the range k2 ∈ [2, 5].
It is important to note that the width of the ‘unstable’ region asymptoti-
cally shrinks with increasing n (Figure 3.2 and Figure 3.3). As can be seen
from Table 3.1, the current largest PPI network contains more than 9000
nodes. Assuming that k2 is in the range k2 ∈ [2, 5], we find that most of the
real-world networks listed in Table 3.1 have edge densities higher than 4/n,
and all of them have edge densities higher than 3/n. Considering the local
densities of real-world networks are much higher than those of uniformly
dense random models (as will be discussed in Section 3.3.4), it is certain
that these networks are dense enough that this ‘instability’ does not affect
their analysis.
3.3.3. Effect of more up-to-date PPI data
Rito et al. (2010) analysed six PPI networks of yeast and human, but all
of these networks are not only out-of-date now, but was also out-of-date
at the time of their study (Figure 3.7). For yeast, Rito et al. (2010) used
two PPI networks: one was the earliest Y2H data collected by Ito et al.
(2001) [17] with only about 800 nodes and 800 edges; the other was the
earliest MS-based high confidence PPI data collected by von Mering et al.
(2002) [151] with about 1,000 nodes and 2,500 edges. For human, they used
the first two Y2H studies of the human interactome: one was collected by
Stelzl et al. (2005)[18] with only about 1,700 nodes and 3,000 edges, and
the other was collected by Rual et al. (2005) [19] with about 3,000 nodes
and 6,700 edges. Rito et al. (2010) also analysed PPI data obtained from
BioGRID, but they split the data up into two PPI networks: one with only
PPIs from Y2H experiments and the other with only PPIs from MS-based
experiments. By doing this, they decreased the coverage and density of
the currently available human PPI network, while increasing false negative
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Figure 3.7.: A timeline of PPI data available since 2000. Above the time-
line are PPI data used by Rito et al. (2010) [13]; below the
timeline are data that could have been used by them but were
not, resulting in lower edge densities in the PPI networks they
studied.
rates of the two PPI networks they constructed. For these reasons, PPI
networks analysed by Rito et al. (2010) have much lower edge density than
recently available PPI networks. Thus their conclusion does not hold for
more up-to-date PPI data.
3.3.4. Local density vs. average density
It is crucial to distinguish between local and average density. Rito et al.
(2010) analysed random model networks with the same average density
(i.e., the edge density of the whole network) of data networks. However,
data networks have local densities much higher than a uniformly dense ER
or GEO model would have [154, 5, 155]. Table 3.2 shows the edge density
at which Rito et al. (2010) [13] expected the first graphlet to appear, along
with the actual graphlet frequencies of two human PPI networks HS and
HG. As can be seen, even the earliest human PPI networks have much more
large-, dense-graphlets than one would expect in an ER or a GEO model
with the same average densities of these PPI networks. For example, the
PPI network HG contains 19 copies of graphlet G28 (see Figure 2.6 for all 30
graphlets with 2-5 nodes). However, this graphlet is expected to appear in
an ER model with 2000 nodes until the edge density reaches 0.02495. Since
HG has about 2,000 nodes and an edge density of 0.00198, this expected edge
density is about 12 times higher than the actual density of HG. Even for a
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GEO model, the expected edge density of one graphlet G28 to appear in the
network is about 0.0025, which is still much higher than HG’s edge density.
In addition, HG contains millions of distinct 5-node graphlets, while model
networks are expected to contain only a few of them. Similar observations
hold for the PPI network HS. These observations demonstrate that PPI
networks are not uniformly dense, but instead contain highly dense sub-
regions where the topology (and hence graphlet-based measures) is stable.
This is also confirmed by a well established observation that PPI networks
have higher clustering coefficients than model networks [5].
We further illustrate this effect on the human PPI network HS by finding
dense sub-regions of the network. To do this, we used the Highly Connected
Subgraph (HCS) algorithm proposed by Hartuv and Shamir (2000) [156] for
graph partition. The largest subgraph of HS found by the HCS algorithm
contains 158 nodes (that is, over 10% of the nodes in HS) and 744 edges
(about 28% of the edges in HS); it has an edge density of 0.05999, which is
about 26 times higher than the density of HS (Figure A.2). Assuming that
k2 is in the range k2 ∈ [2, 5] (discussed in Section 3.3.2), for a network of
n = 158 nodes, the ‘unstable’ region would span the edge density region ρ ∈
[0, 0.03165] (the worst-case, when k2 = 5). A density of 0.05999 is obviously
much higher than the upper bound of the ‘unstable’ region, thus GDD
agreement is stable when measuring the properties of this dense subgraph.
3.3.5. Interpreting the results of non-parametric tests
Graphlet-based measures provide a way to compare two networks according
to the statistical distribution of graphlets. Based on GDD agreement, Rito
et al. (2010) [13] provided a non-parametric test for assessing the fit be-
tween random model networks and real PPI networks. Two distributions of
GDD agreement scores are generated in this test: one is for model-vs-model
comparisons and the other is for data-vs-model comparisons. To obtain the
distribution of GDD agreement scores for model-vs-model comparisons, we
generated a number of model networks with the same size and density as the
PPI network, and computed GDD agreement scores across all pairs of these
model networks. We also calculated GDD agreement scores between the
PPI network and these random model networks to get the distribution of
data-vs-model comparisons. The difference between these two distributions
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ER 1000 ER 2000 GEO 1000 GEO 2000 HG HS
G1 0.00008 0.00003 ∼ 0.0011 ∼ 0.0004 76807 36776
G2 0.00182 0.00091 ” ” 394 86
G3 0.00029 0.00011 ∼ 0.0033 ∼ 0.0013 675350 296346
G4 0.00029 0.00011 ” ” 2018299 435650
G5 0.00221 0.00111 ” ” 10143 9559
G6 0.00221 0.00111 ” ” 38731 6185
G7 0.00752 0.00432 ” ” 2053 154
G8 0.01698 0.01070 ” ” 20 1
G9 0.00059 0.00025 ∼ 0.0060 ∼ 0.0025 9056316 3438523
G10 0.00059 0.00025 ” ” 32102612 7462899
G11 0.00059 0.00025 ” ” 54733928 5067616
G12 0.00261 0.00130 ” ” 915264 123138
G13 0.00261 0.00130 ” ” 265484 43393
G14 0.00261 0.00130 ” ” 1433133 118173
G15 0.00261 0.00130 ” ” 19242 5491
G16 0.00261 0.00130 ” ” 1466355 740181
G17 0.00702 0.00394 ” ” 237849 9495
G18 0.00702 0.00394 ” ” 3743 274
G19 0.00702 0.00394 ” ” 36440 4754
G20 0.00702 0.00394 ” ” 54512 44519
G21 0.00702 0.00394 ” ” 18534 4585
G22 0.01426 0.00869 ” ” 17671 177
G23 0.01426 0.00869 ” ” 2196 148
G24 0.01426 0.00869 ” ” 2420 179
G25 0.01426 0.00869 ” ” 2162 463
G26 0.02426 0.01573 ” ” 409 13
G27 0.02426 0.01573 ” ” 103 9
G28 0.03667 0.02495 ” ∼0.0025 19 0
G29 0.05104 0.03609 ” ” 0 0
Table 3.2.: Graphlet frequencies in model and PPI networks. To the left
of the double vertical line, we reproduce parts of Tables 2 and
3 from Rito et al. (2010) [13]. These numbers represent the
approximate edge density at which Rito et al. (2010) expected
the first graphlet of the type specified in column 1 to appear
in a model network of either ER (columns 2 and 3) or GEO
(columns 4 and 5) type with 1000 (columns 2 and 4) or 2000
(columns 3 and 5) nodes. To the right of the double vertical
line are the actual frequencies of each graphlet type in human
PPI networks HG (column 6, n = 1873, ρ = 0.00198) and HS
(column 7, n = 1529, ρ = 0.00228). The highlighted numbers in
row G28 are discussed in the text.
can be used to evaluate the model fit. Thus if a particular PPI network
is truly well-fit by a particular model, we would expect the GDD agree-
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ment distribution for data-vs-model comparisions to be the same as the one
for model-vs-model comparisons. This non-parametric test allows us to see
whether the data network is statistically distinguishable from the model
networks based on a given measure of network similarity.
However, Rito et al. (2010) used the amount of overlap between the
two distributions (i.e., the model-vs-model GDD agreement distribution
and the data-vs-model GDD agreement distribution) as a binary criterion
for whether the data network is fit by the model, without considering the
actual values of GDD agreement scores. We believe that this interpreta-
tion is too restrictive. For example, consider the following two cases for
a given data network: (A) Model A has model-vs-model GDD agreement
scores distributed normally around 99%± 0.5% and has data-vs-model GDD
agreement scores distributed normally around 97%±0.5%; (B) Model B has
model-vs-model GDD agreement scores distributed normally around 80%±
15% and has data-vs-model GDD agreement scores distributed normally
around 70%± 15%. By considering only the amount of overlap between
the two distributions, the non-parametric test would suggest that Model B
better fits the data than Model A, since case (B) has substantial overlap
between distributions while case (A) has none. However, a GDD agree-
ment score of 97% (case (A)) is certainly (assuming the model is derived
independently of the data) better than a GDD agreement score of just 70%
(case (B)). The absolute value of GDD agreement between the data net-
work and the model network is an important criterion of the topological
similarity between them. Since the models we analysed are still preliminary
and purely empirical, it is possible that the model may be too narrowly
defined thus the two distributions have no overlap. For example, adding a
small amount of noise to Model A (to mimic noise in the data) might lead
to higher data-vs-model GDD agreement scores and lower model-vs-model
scores thus provide a large amount of overlap as well as a high GDD agree-
ment score. It is not clear to us that overlap between two distributions
should be the sole criterion for judging how well a model fits the data.
3.3.6. Modelling viral PPI networks
Current PPI networks are still noisy and largely incomplete (discussed in
Section 2.1.1). For example, bacterial PPI networks SPP and MZL (Table
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Figure 3.8.: Comparing six random network models to the PPI networks of
five species of herpesvirus [26] using the non-parametric test
described in Rito et al. (2010) [13]. Each row represents one
theoretical model, and each column represents one viral PPI
network. The horizontal axis is the GDD agreement score, and
the vertical axis is measured probability density. In each fig-
ure, the blue bars represent a histogram of GDD agreement
scores across all pairs of 30 randomly generated model networks
with the same size and density as the corresponding PPI net-
work. The red bars represent a histogram of the GDD agree-
ment scores of the viral PPI network compared to the same 30
model networks.
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VZV KSHV HSV-1 mCMV EBV Mean StdDev
ER 0.0000 0.0000 0.0092 0.0000 0.0000 0.0018 0.0041
SF-RND 0.2667 0.0299 0.369 0.0000 0.0000 0.1331 0.1729
GEO 0.0161 0.0368 0.1782 0.0069 0.0529 0.0581 0.0694
GEO-GD 0.3931 0.2839 0.5264 0.3586 0.3897 0.3903 0.0878
SF-GD 0.4299 0.2046 0.5000 0.5483 0.0966 0.3558 0.1958
STICKY 0.5517 0.1138 0.7207 0.7414 0.4299 0.5115 0.2564
Table 3.3.: Overlap amounts (shared area under the curve) for histograms
shown in Figure 3.8.
3.1) have about a 50% false-negative rate [148, 147]; the PPI network AT
covers only 2% of the interactome of A. thaliana. Compared with other PPI
networks listed in Tabel 3.1, the five viral PPI networks (HSV-1, KSHV,
VZV, EBV and mCMV) are substantially complete in the sense that all
possible pairs of proteins were tested for interaction [26]. We compared
these complete PPI networks to six random network models using the non-
parametric test described above. Figure 3.8 depicts distributions of GDD
agreement scores of data-vs-model comparisons and model-vs-model com-
parisons, and the overlap amounts are shown in Table 3.3. We find that the
STICKY model is the best-fitting to these networks, as it has the greatest
amount of overlap with four of the five viral PPI networks. The SF-GD
model appears to be the second best, followed by GEO-GD, GEO, ER-DD
(SF-RND) models (in that order). As expected, the ER model is the worst
fitting model compared to the others since there is almost no overlap be-
tween the data-vs-model distribution and the model-vs-model distribution
for the five viral PPI networks. To our knowledge, this is the first time
that the structure of viral PPI networks has been modelled. Examining the
biological reasons for the good fit of the STICKY model and why it is a less
good fit for the PPI network KSHV is a subject of future research.
Similar plots for the other PPI networks listed in Table 3.3 can be found in
Figure A.4. These plots also indicate that STICKY, SF-GD, and GEO-GD
models are the best fitting models for these PPI networks.
3.4. Conclusions
In this chapter, we examined the use of graphlet-based measures for bio-
logical network comparison. By generating the empirical distributions of
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GDD agreement scores, we identified the edge density regions in which the
topology of model networks is ‘unstable’, and showed how graphlet-based
measures correctly detect this topological instability. The ‘unstable’ re-
gions do not affect the analysis of current PPI data, since current PPI data
is dense enough to avoid these regions. We showed that data networks have
high local densities thus graphlet-based measures are ‘stable’ in regions that
are of interest in real networks.
We have also validated the use of GDD agreement for finding well-fitting
random models for PPI networks. We showed for the first time that five viral
PPI networks are well-fit by several network models (STICKY, SF-GD, and
GEO-GD). We believe that this is a significant milestone in the modelling
of biological networks. Though the biological significance of the fits is not
immediately clear, the fact that we now have reasonably well-fitting models
of viral PPI networks is a stepping stone towards understanding complex
biological systems. Evaluating how and why these models are not perfect,
examining why the STICKY model is often but not always the best fitting
model, and improving current models, is a subject of future research.
3.5. Author’s contributions
In the work presented in this chapter, Kai Sun collected all the data, ran
all the experiments and analysis, helped interpret the results, and prepared
all figures.
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4. Novel insight into
disease-disease associations
Current knowledge of the relationship between diseases is mainly based
on the similarity of clinical phenotypes. However, such knowledge could
be greatly improved by considering the molecular causes and the under-
lying biological mechanisms of diseases. Further understanding of disease
associations based on system-level biological data is expected to lead to
improvements in disease diagnosis, prognosis and treatment.
In this chapter, we present three similarity measures for predicting dis-
ease associations. We take advantage of diverse biological data including
disease-gene associations and a large-scale molecular network to gain novel
insights into disease relationships. We analyse and compare four publicly
available disease-gene association datasets, and apply three measures to es-
timate the similarity scores between diseases. We systematically evaluate
disease associations obtained by our measures against a statistical measure
of comorbidity which was derived from a large number of medical patient
records. Our results show that the correlation between our similarity scores
and comorbidity scores is substantially higher than expected at random,
confirming that our similarity measures are able to recover comorbidity as-
sociations. We also demonstrate that our predicted disease associations
correlate with disease associations generated from GWAS data significantly
higher than expected at random. Furthermore, we evaluate our predicted
disease associations via mining the literature on PubMed, and present case
studies to demonstrate how these novel disease associations can be used to
enhance our current knowledge of disease relationships.
The work presented in this chapter is in collaboration with Dr. Joana
Gonc¸alves and Dr. Chris Larminie. The related manuscript is submitted.
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4.1. Motivation
Correct diagnosis is critical for effective treatment and prevention of dis-
ease. As a result, disease classification has become a cornerstone of modern
medicine. Disease may be classified by any one of a number of criteria:
topographic, anatomic, pathological, physiological, etiological, juristic, epi-
demiological or statistical approaches. However, without considering the
molecular mechanisms driving diseases, such knowledge is limited and can
even be misleading. For example, a common phenotype can be caused by
different underlying mechanisms, such as breast cancer, which can be di-
vided into several subgroups that are characterized by distinct patterns of
pathway activation [58]. Meanwhile, a common mechanism may lead to dif-
ferent phenotypes. For example, a mutation at the β-globin locus may lead
to sickle-cell anemia with different phenotypes such as bony infarcts, acute
chest syndrome and stroke [157].
During the past decade, a wealth of biological data has been generated
from various large-scale genomic studies, prompting the scientific commu-
nity to gain deeper insight into disease relationships based on their underly-
ing biological mechanisms. Various types of biological data have been used
to infer associations between diseases. One of the most commonly used
biological data is disease-gene association. In a broad definition, a disease-
gene association is a connection reported in the literature, which can be a
genetic association (i.e., mutations in that gene may lead to that disease), or
a connection inferred from other aspects. Disease-gene associations can be
obtained from large-scale knowledge-bases such as the OMIM database [64].
Early studies used text mining to infer similarities between phenotypes con-
tained in OMIM, and found those similarities were positively correlated with
a number of measures of gene functions [65] and could be used to predict
disease-causing genes [66]. Also by using OMIM, Goh et al. [67] constructed
the human diseasome by connecting diseases that share a disease-causing
gene. Other types of biological data such as biological pathways [57], gene
expression data [81, 140], biomedical ontologies [141, 139], and GWAS data
[137, 158, 138], have also been used to improve the current understanding of
disease relationships from different aspects. Recently, networks have been
used to model large-scale biological data, and network topology is beginning
to provide insights into diseases and their associations [67, 144, 88, 42]. By
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considering the interconnectivity of biomolecules in the cell, the topology
of biological networks is expected to have various biological and clinical
applications [14, 41].
However, early studies still have several limitations when inferring dis-
ease associations from biological data. First, some studies only considered
several specific diseases, rather than giving a global comparison among all
diseases. This is the case for GWAS-based studies, e.g., [137], since only a
small number of GWAS studies have been completed to date in a relatively
small proportion of the total disease population. Furthermore, most studies
solely used OMIM as the source of disease-gene association data. OMIM
is a catalogue of mendelian disorders and as a result most diseases are an-
notated with few genes in OMIM [159]. Limitations of using OMIM have
also been discussed previously [160, 161]. Finally, most computationally
predicted disease associations were not systematically evaluated due to the
difficulty in identifying a suitable benchmark of known disease associations.
In particular, most studies were only able to validate part of their results
by comparing them with phenotypic similarities or mining the literature
manually. A comparison of previous studies can be found in Table 4.1.
In the study presented in this chapter, we used diverse biological data
from a number of repositories to gain novel insights into the relationship of
all known human diseases by considering their underlying biological mech-
anisms. We used disease-gene associations obtained from four different
sources to avoid the bias introduced by a single dataset. Moreover, we took
advantage of the topology of a large-scale molecular network to examine
its use for inferring disease associations. We applied three different dis-
ease similarity measures, namely annotation-based measure, function-based
measure and topology-based measure, to estimate similarity scores between
diseases. The disease associations obtained by the three measures were sys-
tematically evaluated against the ICD disease classification system, and a
statistical measure of comorbidity derived from a large number of medical
patient records. In addition, we evaluated our predicted disease associa-
tions by using disease associations generated from GWAS studies, which
represent one of the most robust routes for identifying causal relationships
between genes and diseases. To our knowledge, this is the first time that
network topology has been used to infer disease-disease associations.
In the rest of this chapter, we will start with a description of the biological
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Reference Data Size Evaluation
van Driel et al.
(2006) [65]
OMIM 5132
phenotypes in
OMIM
Comparing results
with genotypic simi-
larities
Lage et al.
(2007) [66]
OMIM 7000 OMIM
record pairs
Evaluating results
against the overlap
of the OMIM record
pairs
Goh et al.
(2007) [67]
OMIM 1284 OMIM
diseases
Analysing network
topological properties
Huang et al.
(2009) [137]
GWAS 7 diseases Comparing results
with phenotypic
similarities
Li and Agarwal
(2009) [57]
Pubmed
abstracts,
biological
pathways
1028 diseases
in MeSH
Comparing results
with MeSH classifica-
tion
Kim et al.
(2009) [158]
GWAS 53 clinical
traits related to
severe asthma
Mining the literature
manually
Hu and Agarwal
(2009) [81]
Expression
data
645 diseases in
MeSH
Comparing results
with MeSH classifica-
tion
Suthram et al.
(2010) [140]
Expression
data, PPI
54 diseases Evaluating results
against genetic simi-
larities
Lewis et al.
(2011) [138]
GWAS 61 diseases Comparing results
with Huang et al.
(2009) results
Mathur and
Dinakarpandian
et al. (2007)
[141]
DO
annotation,
GO annotation
36 diseases (for
evaluation)
Evaluating results us-
ing 68 curated disease
associations
Our study Disease-gene
associations,
PPI, GO
annotation
543 ICD-9
diseases
Evaluating results
against ICD-9, comor-
bidity, and genetic
similarities derived
from GWAS data
Table 4.1.: Comparison of studies on inferring disease association. The com-
parison is based on the data used to derive associations (denoted
by ’Data’), number of diseases evaluated (denoted by ’Size’) and
benchmarks used for evaluation (denoted by ’Evaluation’). The
number of diseases evaluated in our study is computed as the
union of diseases annotated in the four disease-gene association
datasets we analysed, given in Figure 4.1.
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data we analysed, followed by details of our methodology of measuring dis-
ease associations. Then we will show and discuss the evaluation of disease
associations predicted by our similarity measures against known disease as-
sociations derived from ICD-9, comorbidity data and GWAS data. Finally,
we will present case studies to demonstrate the ability of our similarity
measures to predict novel disease associations.
4.2. Methods
4.2.1. Biological data
Three types of biological data were used in this study: PPIs, GO annotations
and disease-gene associations.
PPI network
As described in Section 2.1.1, a PPI network models the physical interac-
tion among proteins in the cell, in which a node represents a protein, and
an undirected edge exists between a pair of nodes if their corresponding
proteins can physically bind to each other. Currently available PPIs are
mostly yielded from various high throughput proteomics experiments, such
as yeast two-hybrid screening (e.g., [18]) and affinity capture mass spectrom-
etry (e.g., [25]). We constructed a human PPI network using data obtained
from BioGRID [30] version 3.1.93 (released in October 2012). All self-loops,
duplicate interactions and inter species interactions were removed since we
considered only simple, undirected graphs. We used the largest connected
component of this PPI network for computation, which contains 11,261
nodes and 66,253 edges.
GO annotations
Genes are annotated with GO terms to represent their biological properties
[162]. All GO terms are organised in three domains: cellular component,
molecular function and biological process. We downloaded the ontology
file and annotations of Homo sapiens from the Gene Ontology database1 in
November 2012. We removed annotations with evidence code ‘Inferred from
1http://www.geneontology.org
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Electronic Annotation’ (IEAs), since IEAs are computationally inferred an-
notations which have not been reviewed by curators. In total, we collected
171,888 annotations between 13,166 genes and 10,787 GO terms.
Disease-gene associations.
Disease-gene associations can be modelled as a graph containing both known
human diseases and disease-related genes in the human genome. The degree
of a disease is the number of genes associated with that disease, while the
degree of a gene is the number of diseases annotated with that gene. We
used four disease-gene association datasets obtained from different sources:
OMIM, CTD [68], Functional Disease Ontology annotations (FunDO) [163]
and Human Genome Epidemiology Network (HuGENet) [164]. Among
these datasets, OMIM, CTD, and FunDO contain curated associations,
while HuGENet contains computationally inferred associations. Details of
these disease-gene association datasets are described below.
• OMIM is considered to be the best curated resource of phenotype-
genotype relationships, and it has been used in various disease-related
studies (discussed in Section 4.1). We downloaded the OMIM database
in November 2012. In total, it contains 3,537 diseases (annotated by
OMIM IDs), 2,862 genes and 4,337 disease-gene associations.
• CTD provides scientific data describing relationships between chemi-
cals, genes, and human diseases, with the goal of improving the under-
standing of environmental chemicals’ effects on human health. It con-
tains both curated and inferred disease-gene associations, but we only
used curated associations as they have higher confidence than inferred
associations. Disease-gene associations directly derived from OMIM
were excluded to reduce the dependency between datasets. We down-
loaded the data from CTD in November 2012 and obtained 17,754
associations between 2,761 diseases (annotated by MeSH terms2) and
5,828 genes.
• FunDO contains disease-gene associations extracted from the NCBI
Gene Reference Into Function (GeneRIF) database. A GeneRIF is a
brief statement about the function of a gene, along with information
2http://www.nlm.nih.gov/mesh/
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of its association with diseases. We downloaded the latest stable ver-
sion of FunDO (released in October 2008) and obtained 1,854 diseases
(annotated by Disease Ontology (DO) terms), 4,781 genes and 28,442
disease-gene associations.
• HuGENet is known as an integrated knowledge-base on human genome
epidemiology. The Phenopedia collection of HuGENet contains disease-
gene associations obtained by text-mining of abstracts on PubMed us-
ing machine learning techniques. Disease-gene association data were
downloaded via HuGE Navigator in September 2012. We obtained
353,883 associations between 2,387 diseases (annotated by Unified
Medical Language System (UMLS) Concept Unique Identifiers (CUIs)3)
and 11,915 genes.
Since disease names or IDs used in these datasets are based on different
labelling schemes, we mapped all disease names or IDs to ICD-9 codes, for
the purpose of comparing these datasets and further evaluation (also see
Section 4.3.2 for details). We used the mapping manually constructed by
Goh et al. (2007) [67] and Park et al. (2009) [133] to convert OMIM IDs to
ICD-9 codes, and used the corresponding mapping provided in DO version
3 (the latest stable version of DO, released in May 2007) to map DO IDs,
MeSH terms and UMLS CUIs to ICD-9 codes. In total, 1,467 OMIM IDs
in OMIM, 423 MeSH terms in CTD, 806 DO IDs in FunDO and 693 UMLS
CUIs in HuGENet were mapped to ICD-9 codes.
4.2.2. Disease similarity measures
We applied three similarity measures to estimate similarity scores between
diseases. These measures include standard methods (e.g., Jaccard index)
and novel measures proposed in this study (e.g., graphlet-based measure).
Considering the information used in calculation, the similarity score of a
pair of diseases was measured in three different ways: annotation-based,
function-based and topology-based.
3http://www.nlm.nih.gov/research/umls/
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Annotation-based measure.
The annotation-based measure solely used the information obtained from
disease-gene association data. We applied the Jaccard index, which is known
as a standard method for comparing the similarity between two sets, to
estimate the similarity score between diseases as follows. Let GDi be the
set of genes associated with a disease Di. We computed the annotation-
based similarity score of two diseases Di and Dj as the Jaccard index (or
Jaccard similarity coefficient) of GDi and GDj :
Simannotation(Di, Dj) =
|GDi ∩GDj |
|GDi ∪GDj |
. (4.1)
Note that the F-measure, which corresponds to the Sørensen-Dice coef-
ficient [165] in set theory, can also be applied to measure the similarity
between GDi and GDj . Since it has been shown that the Sørensen-Dice
coefficient is monotonically related to the Jaccard index [166], the choice
between the two measures does not affect our results.
Function-based measure.
The function-based similarity measure used both GO term annotations and
disease-gene associations to estimate the similarity score between a pair of
diseases. For each disease Di annotated in a specific disease-gene association
dataset, we first identified the set of GO terms that were overrepresented
within GDi , denoted by GODi . The statistical significance (p-value) of the
enrichment of a GO term was computed according to the hypergeometric
distribution for sampling without replacement, and was corrected for mul-
tiple testing using the Benjamini-Hochberg test [167]. We used Benjamini-
Hochberg correction rather than Bonferroni correction to control the false
discovery rate since Bonferroni correction has been considered to be too
conservative if the number of tests is large [168]. Therefore, only overrep-
resented GO terms from the ‘biological process’ domain of GO and having
a p-value less than 0.05 were considered to be in GODi . Then for a pair of
diseases Di and Dj , we computed the Jaccard index of GODi and GODj as
their function-based similarity score, defined as:
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Simfunction(Di, Dj) =
|GODi ∩GODj |
|GODi ∪GODj |
. (4.2)
Topology-based measure.
The topology of PPI networks has yielded insights into biological function
and disease (e.g., [46]). Topological similarities of proteins in a PPI network
are considered as a complementary information to sequence similarities [39].
Thus in this study, we took advantage of the topology of the human PPI
network along with disease-gene association data to examine the use of net-
work topology for uncovering novel disease associations. We hypothesised
that the underlying biological mechanisms of diseases would be reflected by
the topological property of the human PPI network. In particular, we pro-
posed a measure to estimate the similarity score between a pair of diseases
based on the topological similarity of their annotated genes.
We applied a graphlet-based method to assess the topological similarity of
genes in the human PPI network. As described in Section 2.2.4, a graphlet
is defined as a small, connected and induced subgraph of a larger network
[5]. Topologically identical nodes within a graphlet are said to belong to
the same automorphism orbit [6]. The graphlet signature of a node u is a
73-dimensional vector, whose ith element ui counts the number of times the
node u is touched by the particular automorphism orbit i [46]. According
to Milenkovic´ and Przˇulj (2008) [46], the signature similarity of a pair of
nodes u and v is defined as:
SigSim(u, v) = 1− 1∑72
i=0wi
(
72∑
i=0
(wi × | log(ui + 1)− log(vi + 1)|
log(max{ui, vi}+ 2) )) (4.3)
where wi is a weight assigned to orbit i defined as 1− log(oi)/log(73) (oi is
the dependency count of orbit i, see [46] as well as Section 2.2.4 for details).
We calculated the signature similarity of each pair of genes in the human
PPI network. Note that the network has an edge density (the proportion of
the number of edges to the maximum possible number of edges) of 0.001,
which for its size (11,261 nodes and 66,253 edges) is dense enough to avoid
low edge density regions in which the topology of networks is unstable (see
[106] and Chapter 3 for details). We extended the use of graphlet-based
method to measure disease similarities. We introduced two terms to quan-
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tify the topology-based similarity score between diseases Di and Dj . The
first term, denoted by AllSig, is the maximum of the signature similarity
between a gene in GDi and a gene in GDj :
AllSig(Di, Dj) = max
gm∈GDi
gn∈GDj
SigSim(gm, gn). (4.4)
The second term, denoted by ShareSig, focuses on the topological simi-
larity between genes shared between both diseases:
ShareSig(Di, Dj) = max
gm 6=gn
gm∈GDi∩GDj
gn∈GDi∩GDj
SigSim(gm, gn). (4.5)
Finally we defined the topology-based similarity score between Di and Dj
as the average of these two terms:
Simtopology(Di, Dj) =
1
2
× (ShareSig(Di, Dj) +AllSig(Di, Dj)). (4.6)
4.2.3. Evaluation
Comorbidity associations of diseases.
The availability of electronic patient records facilitates studies into disease
comorbidity, which indicates the potential for co-occurrence of two given
diseases in the same individual. Comorbidity can be considered as a type
of disease-disease association derived from electronic medical records, but
the underlying drivers for comorbidity may be very different from one an-
other. Comorbidity and its correlation with other types of disease associa-
tions such as genetic associations [145] and evolutionary associations [134]
have previously been studied. Unlike these studies, we used comorbidity
data to evaluate disease associations predicted by our similarity measures.
Comorbidity associations were downloaded from the Human Disease Net-
work (HuDiNe, [132]), which were obtained from the disease history of 32
million American patients. Diseases were annotated using ICD-9 codes in
HuDiNe, and as many diseases in patient records were not specific enough
to map to 4-digit or 5-digit codes, we used the comorbidity data annotated
using 3-digit level ICD-9 codes for our analysis. The strength of comorbid-
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ity association between a pair of diseases can be measured by the Relative
Risk and φ-correlation [132]. Because comorbidity associations quantified
by φ-correlation were reported to contain more connections across different
ICD-9 categories [132], we chose φ-correlation as the measure of comoridity.
The φ-correlation score between Di and Dj was defined as the Pearson’s
correlation for binary variables, given by:
φ(Di, Dj) =
CijN − PiPj√
PiPj(N − Pi)(N − Pj)
(4.7)
where Cij is the number of individuals affected by both Di and Dj , N is the
total number of individuals in the population, Pi and Pj are the prevalences
of Di and Dj respectively. A φ-correlation higher than 0 indicates the co-
occurrence of Di and Dj is more frequently than expected by random. The
statistical significance of φ-correlation was determined by using a t-test,
t =
φ
√
n− 2√
1− φ2 (4.8)
where n = max(Pi, Pj) is the number of observations used to calculate φ.
We used significant associations at 5% level (t ≥ 1.96) for our analyses.
GWAS data.
GWAS is a powerful method for identifing genetic variations associated with
diseases and is one of the most robust routes for identifying causal relation-
ships between genes and diseases [70, 72]. As described in Section 2.1.3,
GWAS studies examine the genome for SNPs that occur more frequently
in people with a particular disease than in people without it. GWAS stud-
ies have enabled exploration of gene association in complex diseases in a
systematic way on a genome scale. Whilst individual studies are extremely
powerful, only a small number of diseases have been studied thus far using
GWAS. Hence the GWAS database as a whole is only able to contribute a
relatively small component to the overall knowledge base of general disease-
gene associations. For this reason, we did not use GWAS data as a source
of disease-gene association to measure disease similarity scores, but used
them to evaluate our predicted disease associations. Note that for simplic-
ity, we assume independency of SNPs in our analysis. It is possible that
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some of the SNPs are highly correlated, i.e., in high linkage disequilibrium
(LD). Despite several methods having been proposed to account for LD in
GWAS data, such methods may increase the risk of including false positives
[169]. In addition, our current knowledge of the dependencies of SNPs is
still limited. For example, the interrelationships between driver SNPs (mu-
tations that drive the development and progress of cancer) and passenger
SNPs (mutations that occur as cancer progresses but have no effect on the
disease) are still poorly understood [170]. For these reasons, although the
dependencies between SNPs are typically present in GWAS data, we did
not take them into account in our study.
We downloaded GWAS data from the NHGRI GWAS catalog [73] in
May 2013. This resource collects significant associations between traits (or
diseases) and SNPs from the literature. Similar to Sanseau et al. (2012)
[84], we only considered highly confident associations with p-value lower
than 10−7. We also eliminated not replicated associations to minimize
false-positives. For all disease-SNP associations, we used the corresponding
disease-gene associations reported by the authors in the original publica-
tions in our analysis. After mapping diseases to ICD-9 codes, we obtained
1,756 genetic associations (from 478 publications) between 126 diseases and
1,298 genes.
4.3. Results and discussion
4.3.1. Comparison of disease-gene association datasets
We analysed four different disease-gene association datasets: three curated
datasets, namely OMIM, CTD and FunDO, and one computationally pre-
dicted dataset, HuGENet. Although these datasets focus on different as-
pects of the connections between diseases and genes, they are not fully
independent since information contained in these datasets is extracted from
the literature. For example, disease-gene associations contained in CTD and
FunDO were extracted from 9,269 and 48,436 publications respectively, and
they have 799 publications in common. We mapped all disease names or IDs
annotated in these datasets to ICD-9 codes for a correct comparison (see
Section 4.2.1). If several diseases were mapped to a common ICD-9 code,
we assigned the union of genes associated with those diseases to that ICD-9
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Figure 4.1.: The overlap of diseases (denoted by ‘D’), genes (denoted by
‘G’) and their associations (denoted by ‘A’) between the four
disease-gene association datasets we analysed. Each ellipse in
the Venn diagram represents a disease-gene association dataset.
The interior of an ellipse symbolically represents the elements
(i.e., diseases, genes and associations) annotated in the cor-
responding dataset, while the exterior represents elements that
are not annotated in that dataset. For example, 23 diseases, 122
genes and 1127 disease-gene associations annotated in OMIM
are not annotated in the other three datesets, as shown by blue
numbers in the Venn diagram. Boxes on the left list the sizes
of the four datasets. The size of the intersection of the datasets
is marked in bold.
code. In order to evaluate our measures using comorbidity data, we further
limited the ICD-9 codes to 3-digit level. We are aware that noise may be
introduced when merging diseases into 3-digit level. Generally speaking, a
3-digit level ICD-9 code is always associated with more than one disease,
thus the average degree of diseases increased after mapping.
Interestingly, the overlap among the four disease-gene association datasets
is unexpectedly small, as shown in Figure 4.1. While a considerable num-
ber of diseases (120 diseases in total, that is, 50.21%, 47.43%, 26.20% and
33.33% of diseases annotated in OMIM, CTD, FunDO and HuGENet, re-
spectively) have gene annotations in all four datasets, few disease-gene asso-
ciations (159 associations in total, that is, 7.05%, 1.99%, 0.92% and 0.11%
of associations in OMIM, CTD, FunDO and HuGENet, respectively) can
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be found in all datasets. Figure A.7 further demonstrates the difference
between these datasets according to the degree distribution of diseases. In
general, these distributions follow power law distributions, indicating that
most human diseases are associated with only a few disease genes, while
a small number of diseases relate to many genes. However, this scale-free
topology may also be an artifact of sampling: several diseases are better
studied than others [52]. We notice that in OMIM, most diseases are asso-
ciated with fewer genes compared with other datasets. The average number
of genes associated with a disease in OMIM is 9.43, while in the two other
curated datasets CTD and FunDO, these numbers are 31.59 and 37.80. On
the other hand, on average a disease in HuGENet is annotated with more
than 300 genes: HuGENet has a higher false positive rate compared to other
datasets, since its associations were derived from computational predictions
rather than manual curations.
The difference and inconsistency discussed above indicate that currently
available disease-gene association datasets are still noisy and incomplete.
The incompleteness may be due to the focus of the datasets and the nature
of the curation process. For example, OMIM mainly focuses on mendelian
diseases and traits. Meanwhile, many false positives may be introduced
by text-mining the literature (e.g., HuGENet). However, there is no single
standard and systematic method to assess the quality of these data. There-
fore, to gain a more comprehensive view of human diseases and to test the
robustness of our methods, we used all four disease-gene association datasets
along with the intersection/union of the three curated datasets in further
computation and evaluation.
4.3.2. Evaluation of similarity measures
Correlation with ICD-9.
The results obtained by these measures were first evaluated against the
standard disease classification system ICD-9. We say that two diseases are
associated according to ICD-9, if they are classified under the same ICD-9
category4. For example, diabetes mellitus (ICD-9 code: 250) and thyroidi-
tis (ICD-9 code: 245) are classified under the same category ‘endocrine,
nutritional and metabolic diseases, and immunity disorders’. To investigate
4http://www.icd9data.com/2013/Volume1/default.htm
76
Data Group Annotation-based Function-based Topology-based
OMIM Same 0.0114 ± 0.0665 0.0355 ± 0.0892 0.4349 ± 0.1101
Different 0.0010 ± 0.0139 0.0118 ± 0.0314 0.3996 ± 0.0760
P-value 1.2785 ×10−13 1.0423 ×10−52 2.1257 ×10−54
CTD Same 0.0361 ± 0.1590 0.0728 ± 0.1754 0.4863 ± 0.1770
Different 0.0050 ± 0.0274 0.0333 ± 0.0662 0.4408 ± 0.1368
P-value 1.4887 ×10−23 1.4040 ×10−9 2.0240 ×10−25
FunDO Same 0.0418 ± 0.1344 0.0991 ± 0.1611 0.5560 ± 0.2214
Different 0.0100 ± 0.0262 0.0549 ± 0.0830 0.4952 ± 0.1636
P-value 1.7609 ×10−144 9.6708 ×10−100 2.7037 ×10−90
HuGENet Same 0.0931 ± 0.1798 0.2470 ± 0.2123 0.8031 ± 0.2248
Different 0.0438 ± 0.0566 0.1881 ± 0.1522 0.7837 ± 0.2292
P-value 1.4585 ×10−74 9.9053 ×10−72 4.5910 ×10−14
Intersection Same 0.0338 ± 0.1511 0.0593 ± 0.1907 0.3826 ± 0.1131
Different 0.0024 ± 0.0329 0.0089 ± 0.0428 0.3496 ± 0.1020
P-value 2.2667 ×10−2 2.7448 ×10−4 5.4716 ×10−4
Union Same 0.0350 ± 0.1179 0.0963 ± 0.1463 0.5680 ± 0.2226
Different 0.0085 ± 0.0219 0.0583 ± 0.0818 0.5042 ± 0.1716
P-value 1.3493 ×10−211 7.1478 ×10−113 4.1709 ×10−141
Table 4.2.: Evaluation of our measures against ICD-9 classification. Num-
bers in the table are similarity scores between diseases from
the same ICD-9 categories, compared with those from differ-
ent ICD-9 categories. P -values are calculated by using the
Mann−Whitney U test.
the correlation between our similarity measures and the ICD-9 classifica-
tion, we tested whether a pair of diseases from the same ICD-9 category
tends to have a higher similarity score than diseases from different ICD-9
categories (Table 4.2). Since similarity scores obtained by our measures are
not normally distributed, we used a non-parametric test, namely the Mann-
Whitney U test, to assess the statistical significance (p-value). Our results
show that for all three similarity measures and all four disease-gene associ-
ation datasets, similarity scores of diseases from the same ICD-9 category
are significantly higher than those from different ICD-9 categories.
Correlation with comorbidity.
As the goal of our study is to uncover novel disease associations that may
reflect common underlying mechanisms, we are more interested in the asso-
ciations between diseases that belong to different ICD-9 categories. For this
reason, we systematically evaluated our similarity measures against a statis-
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tical measure of comorbidity. We say two diseases are associated according
to comorbidity if they are reported to have a significant co-occurrence in the
same individual. In particular, their φ-correlation score should be higher
than a chosen threshold and statistically significant at 5% level. Figure A.8
shows the distribution of φ-correlation scores for all pairs of diseases we
analysed.
To assess the ability of our measures to uncover highly confident co-
morbidity associations, we used Receiver Operating Characteristic (ROC)
curves, in which we plotted the True Positive Rate (TPR, also known as sen-
sitivity) versus the False Positive Rate (FPR, also known as 1−specificity)
for different thresholds of similarity score. TPR is defined as the fraction of
true positives (that is, all pairs of diseases having a similarity score higher
than a chosen threshold and having comorbidity association) out of the
positives (all pairs of diseases having comorbidity association), while FPR
is defined as the fraction of false positives (all pairs of diseases having a
similarity score higher than a chosen threshold but having no comorbidity
association) out of the negatives (all pairs of diseases excluding those hav-
ing comorbidity association). Figure 4.2, Figure A.5, Figure A.6 and Table
4.3 show the ROC curves and Area Under Curve (AUC) values obtained
by the three disease similarity measures. The φ-correlation threshold was
set to 0.06 (the same threshold was used by Hidalgo et al. (2009) [132]).
For each combination of disease-gene association data and disease similar-
ity measure, we evaluated diseases annotated with at least 1, 3, 5, 7, 10,
15 genes, shown by curves with different colours in each plot. For the in-
tersection set, only two curves were shown in each plot since there were
no comorbidity relationships between diseases annotated with more than
5 genes. To illustrate that our results cannot be obtained by chance, we
assigned a randomised score which was drawn from the same distribution
of the similarity scores to each pair of diseases, and evaluated associations
derived from these randomised scores against comorbidity. We show that
the correlation between our similarity measures and comorbidity scores is
substantially higher than expected at random for all disease-gene associa-
tion datasets we analysed. In particular, diseases yielding a high similarity
score are very likely to have comorbidity associations, thus confirming that
our measures are able to uncover known comorbidity relationships.
While varying the φ-correlation threshold, we obtained higher AUC values
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Figure 4.2.: ROC curves obtained by evaluating the topology-based measure
against comorbidity. The φ-correlation threshold was set to
0.06. For each disease-gene association dataset, we evaluated
diseases annotated with at least 1, 3, 5, 7, 10, 15 genes, shown by
curves with different colours in each plot. For the intersection
set, only two curves were shown in each plot since there were no
comorbidity associations between diseases annotated with more
than 5 genes.
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Data Annotation-based Function-based Topology-based
OMIM 0.8009 ± 0.0277 (0.57) 0.8694 ± 0.0073 (0.51) 0.8495 ± 0.0011 (0.50)
CTD 0.7849 ± 0.0164 (0.54) 0.7316 ± 0.0046 (0.50) 0.7949 ± 0.0042 (0.52)
FunDO 0.7426 ± 0.0088 (0.47) 0.7142 ± 0.0017 (0.49) 0.7497 ± 0.0016 (0.50)
HuGENet 0.7563 ± 0.0001 (0.51) 0.8185 ± 0.0001 (0.50) 0.7153 ± 0.0015 (0.49)
Intersection 0.9925 ± 0.0001 (0.60) 0.9802 ± 0.0001 (0.51) 0.9958 ± 0.0041 (0.47)
Union 0.8225 ± 0.0045 (0.47) 0.7491 ± 0.0001 (0.50) 0.7939 ± 0.0022 (0.50)
Average 0.8194 ± 0.0837 (0.53) 0.8106 ± 0.0930 (0.50) 0.8163 ± 0.0907 (0.50)
Table 4.3.: Evaluation of our measures against comorbidity. Numbers in the
table are AUC values obtained by evaluating the three disease
similarity measures against comorbidity associations. The φ-
correlation threshold was set to 0.06, and all diseases annotated
with least 3 genes were evaluated. Average AUC values obtained
by using randomised scores are shown by numbers in brackets.
Each evaluation test was run 30 times to compute the statistics
reported in the table.
for higher thresholds. For example, when the φ-correlation threshold was
set to 0.06, the AUC value was 0.7580 ± 0.0024 (using the topology-based
measure and FunDO as the source of disease-gene associations). When the
φ-correlation threshold was set to 0.08 and 0.10, the AUC value increased
to 0.7669 ± 0.0027 and 0.7996 ± 0.0060, respectively. This indicates our
similarity measures tend to detect strong comorbidity associations with high
φ-correlation. Meanwhile, when we decreased the number of false negatives
in the comorbidity data by lowering the φ-correlation threshold from 0.06
to 0.02, the AUC values we obtained were still higher than expected at
random. For example, when the φ-correlation threshold was set to 0.04 and
0.02 (namely increasing 0.90-fold and 5.41-fold the amount of comorbidity
associations), the AUC values we obtained were 0.7064 ± 0.0019 and 0.6017
± 0.0015, respectively. These results suggest our similarity measures are
robust to high false negatives in the comorbidity data. Better ROC curves
can also be obtained by evaluating diseases annotated with higher numbers
of genes (Figure 4.2, Figure A.5, Figure A.6). From Table 4.3, we observed
that best performances of our similarity measures are achieved by using
highly confident curated disease-gene associations (i. e., the intersection set
of OMIM, CTD and FunDO), with AUC values higher than 0.98.
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Data Annotation-based Function-based Topology-based
F/G 0.7224 ± 0.0010 (0.49) 0.6781 ± 0.0001 (0.50) 0.6863 ± 0.0009 (0.50)
Common 0.7527 ± 0.0010 (0.49) 0.7147 ± 0.0001 (0.50) 0.7555 ± 0.0020 (0.40)
Table 4.4.: Evaluation of our measures against GWAS. Only diseases an-
notated with least 3 genes were evaluated. ‘F/G’ are diseases
having associated genes in both FunDO and GWAS data (99 dis-
eases in total). ‘Common’ are diseases having associated genes
in all four disease-gene association datasets (given in Figure 4.1)
and GWAS data (50 diseases in total). Average AUC values
obtained by using randomised scores are shown by numbers in
brackets. Each evaluation test was run 30 times to compute the
statistics reported in the table.
Correlation with GWAS data.
We further examined the correlation between our predicted disease associa-
tions and currently available highly confident GWAS data (see the Methods
section for details) to see whether our findings are supported by GWAS
studies. A gene is said to be associated with a disease according to GWAS,
if the occurrence of genetic variants (SNPs) within that gene is significantly
higher in people with that disease than in people without it. We say that
two diseases are associated according to GWAS if they share at least one
gene in GWAS data. Since disease-gene associations collected in the four
datasets we analysed were extracted from the literature, genetic associa-
tions reported in GWAS studies may also be collected in these datasets.
To avoid bias in evaluation, we chose FunDO as the source of disease-genes
associations, as it has few overlaps with GWAS data. In particular, since
most GWAS data were published after FunDO’s last stable release (Octo-
ber 2008), only 42 out of 48,436 publications in FunDO were also found in
GWAS data. We removed disease-gene associations collected from the com-
mon 42 publications before computing similarity scores between diseases
using FunDO. Similar to our evaluation against comorbidity, we used ROC
curve analysis to assess the ability of our similarity measures to recover
disease associations derived from GWAS (Table 4.4). For each of the three
measures, we found that the correlation between our similarity measures
and GWAS data is substantially higher than expected at random. This
result further confirms the validity of our methods.
81
4.3.3. Comparison of similarity measures
The three similarity measures, namely annotation-based measure, function-
based measure, and topology-based measure, use different biological infor-
mation to predict disease associations. For a pair of diseases, the annotation-
based measure estimates their similarity score based on the overlap of their
annotated genes, while the function-based measure estimates their similar-
ity score based on the overlap of their associated biological functions derived
from GO annotations. The topology-based measure makes use of the topol-
ogy information derived from the underlying PPI network, and estimates
disease similarity scores based on the topological similarity of their anno-
tated genes. Based on our evaluation, the three similarity measures perform
well in recovering known disease associations. Note that though the AUC
values obtained by the three measures are similar, the predictions can dif-
fer from each other. Figure A.9 shows the overlap of disease associations
predicted by the three measures. When considering the top 5% of the most
associated disease pairs as our predicted disease associations, 14% ∼ 38%
of the predictions that are supported by all three similarity measures.
Our similarity measures are sensitive to the noise in disease-gene associa-
tion data. We notice that prediction performances of our similarity measures
generally decrease with the increase of noise level, thus using the intersec-
tion of curated disease-gene association datasets results in the best per-
formance when predicting comorbidity associations (Table 4.3). Both the
annotation-based measure and the topology-based measure have better per-
formances when using curated disease-gene associations (i.e., OMIM, CTD
and FunDO) than computationally predicted associations (i.e., HuGENet).
However, the function-based measure obtains lower AUC values for cu-
rated datasets CTD and FunDO than the two other similarity measures,
but higher AUC values for HuGENet. In this regard, the function-based
measure may be more appropriate for analysing predicted datasets, while
the annotation-based measure and topology-based measure may be more
appropriate for analysing curated datasets.
The annotation-based measure is straightforward, but has relatively good
performance according to our evaluation. However, as it only uses disease-
gene associations to estimate similarity scores, for a pair of diseases sharing
few genes, their annotation-based similarity score may be low, even if their
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annotated genes are closely related. In particular, the annotation-based
measure is highly affected by the occurrence of pleiotropic genes (genes
that cause multiple phenotypes) in the dataset. We obtained the list of
802 pleiotropic genes from the OMIM Morbidmap by identifying genes that
associated with more than one disease (a similar approach was used in
[171]). To examine the influence of pleiotropic genes on our measures, we
excluded these genes from OMIM and evaluated the performances of our
similarity measures against comorbidity. Not surprisingly, the AUC value
of annotation-based measure dropped to 0.5811, close to expected at random
(0.5740, see Table 4.3). On the other hand, since both the function-based
measure and the topology-based measure use additional data sources (GO
annotations or network topology) to estimate similarity scores, they are less
affected by pleiotropic genes. AUC values obtained by the function-based
measure and the topology-based measure dropped to 0.7816 and 0.7199
respectively, after removing pleitropic genes from OMIM. These results show
the contribution of similarities between specific genes (genes associated with
only one disease) to the prediction performances of our similarity measures.
Since disease-gene association datasets were obtained by different research
groups and approaches, good performances for all datasets confirm the ro-
bustness of our similarity measures in predicting disease associations. In
addition, the topology-based measure is also robust to the noise and incom-
pleteness presented in PPI networks. We evaluated this by using PPI data
obtained from different releases of BioGRID database (Table A.3). Gener-
ally speaking, the performance of the topology-based measure slightly de-
creases when using early PPI networks (Table A.4). However, AUC values
obtained by using these early PPI networks are still substantially higher
than expected at random. This result indicates that the ability of the
topology-based measure to predict disease associations is independent of
the noise and incompleteness level of PPI networks.
4.3.4. Case studies
To demonstrate how our similarity measures can be used for uncovering
novel disease associations, we present a case study for diabetes mellitus
(DM, ICD-9 code: 250). DM is a metabolic disease that affects the body’s
ability to produce or use insulin, a hormone for regulating carbohydrates.
83
It causes hyperglycemia and may lead to severe consequences such as brain
damage, amputations and heart disease [172]. Table 4.5 lists the top 30
diseases associated with DM using the topology-based measure and FunDO
as the source of disease-gene associations.
Among these 30 diseases, we found 6 of them are classified under the
same ICD-9 catalogue (namely ‘Endocrine, nutritional and metabolic dis-
eases, and immunity disorders’) with DM, e.g., ovarian dysfunction (ICD-9
code: 256). Meanwhile, the list also includes 5 diseases that have highly
confident comorbidity associations with DM, e.g., essential hypertension
(φ-correlation: 0.1275). Moreover, 10 diseases are associated with DM ac-
cording to GWAS data, e.g., rheumatoid arthritis (number of shared genes:
8). Apart from these diseases known to be associated with DM (16 in total,
as there are associations supported by multiple evidence), the remaining 14
diseases listed in the table are considered as novel associations predicted by
our measure. We evaluated these associations via text mining the literature
on PubMed5. We are able to confirm all of these associations, including sur-
prising associations such as DM and ‘other cerebral degenerations’ (ICD-9
code: 331). This result highlights the power of our approaches to identify
novel associations between diseases. Further exploration of potential un-
derlying mechanisms shared by these diseases may lead to improvement in
disease diagnosis, prognosis and treatment.
Table A.3 shows another case study for Parkinson’s disease (ICD-9 code:
332).
4.4. Conclusions
In this chapter, we gained novel insights into the relationship between hu-
man diseases by considering their molecular causes and underlying physical
interactions. We used information derived from latest biological data, in-
cluding disease-gene associations, gene functions and the topology of the
human PPI network in our analysis. We applied three different measures to
estimate the similarity score of diseases, and these measures were systemat-
ically evaluated against ICD-9 classification system, a statistical measure of
comorbidity and GWAS data. Our results showed the correlation between
associations predicted by our measures and known disease associations, and
5http://www.ncbi.nlm.nih.gov/pubmed
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Rank Code Disease name Reference
1 239 Neoplasms of unspecified nature PMID: 23639840
2 155 Malignant neoplasm of liver and intra-
hepatic bile ducts
GWAS
3 710 Diffuse diseases of connective tissue GWAS
4 714 Rheumatoid arthritis and other inflam-
matory polyarthropathies
GWAS
5 256 Ovarian dysfunction ICD-9, GWAS
5 278 Overweight, obesity and other hyperal-
imentation
ICD-9, comorbidity,
GWAS
7 401 Essential hypertension Comorbidity
8 295 Schizophrenic disorders PMID: 17474808
9 282 Hereditary hemolytic anemias GWAS
10 289 Other diseases of blood and blood-
forming organs
PMID: 11727971
11 642 Hypertension complicating pregnancy
childbirth and the puerperium
PMID: 18558027
12 365 Glaucoma GWAS
13 135 Sarcoidosis PMID: 23075651
13 414 Other forms of chronic ischemic heart
disease
Comorbidity, GWAS
15 331 Other cerebral degenerations PMID: 20837967
15 332 Parkinson’s disease PMID: 23335160
17 244 Acquired hypothyroidism ICD-9
18 335 Anterior horn cell disease PMID: 22017321
19 362 Other retinal disorders Comorbidity
20 753 Congenital anomalies of urinary system PMID: 22260488
21 277 Other and unspecified disorders of
metabolism
ICD-9
22 286 Coagulation defects PMID: 22460041
23 042 Human immunodeficiency virus [HIV]
disease
PMID: 19419710
24 340 Multiple sclerosis GWAS
24 579 Intestinal malabsorption GWAS
26 272 Disorders of lipoid metabolism ICD-9
27 577 Diseases of pancreas PMID: 22996690
28 287 Purpura and other hemorrhagic condi-
tions
PMID: 21092704
28 290 Dementias PMID: 23543134
28 581 Nephrotic syndrome PMID: 16995591
Table 4.5.: List of the top 30 diseases associated with DM. The topology-
based measure was used as the similarity measure, and FunDO
was used as the source of disease-gene associations. Only dis-
eases annotated in all four disease-gene association datasets are
listed in the table. For a disease associated with DM according
to ICD-9, comorbidity or GWAS, we added the supported evi-
dence to the reference (the last column). The remaining disease
associations were validated via mining the literature on PubMed,
and for each disease only one reference (shown by PubMed ID)
was listed in the table.
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we also demonstrated the use of our measures in discovering novel disease
associations and validated it via literature curation.
Novel disease associations uncovered in this study can be further used to
improve our understanding of disease classification. For example, a human
disease network that models the relationship of diseases can be constructed
based on these similarity measures, and computational approaches, such as
clustering, can be applied to detect communities in the disease network.
This may provide the opportunity to redefine the current disease classifica-
tion and further lead to improvements in disease diagnosis, prognosis and
treatment.
4.5. Author’s contributions
In the work presented in this chapter, Kai Sun collected all the data, de-
signed and implemented the similarity measures, ran all the experiments,
and performed all the analysis.
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5. Biological network integration
In this chapter, we further our results by integrating different types of large-
scale biological data, including GWAS data, disease-chemical associations,
biological pathways and GO annotations, with the aim of gaining more
complete understanding of the relationships between diseases. In partic-
ular, we integrate these data into a heterogeneous network, where nodes
are bio-entities (e.g., genes, diseases, chemicals, pathways and GO terms)
and edges between nodes represent their associations. We extend our disease
similarity measures to an integration-based measure to predict novel disease
associations by mining the heterogeneous network. Our results are system-
ically evaluated against the MeSH classification and a statistical measure
of disease co-occurrence in PubMed. In addition, we show that our similar-
ity measure achieves better performance by using the integrated data than
solely using a specific type of data. To illustrate the use of our approach
to uncover novel diseases associations, we present a case study of Crohn’s
disease, in which we identify its top associated diseases and validate our
predicted associations via mining the literature. We also give examples to
demonstrate how our approach can be used for drug repositioning.
The work presented in this chapter is in collaboration with Dr. Chris
Larminie and Dr. Natalie Buchan. The related manuscript is in preparation.
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5.1. Motivation
Recent advances done in ‘omics’ technologies have lead to a wealth of bio-
logical data. These data, including genetic data (e.g., GWAS data [70, 173,
174, 71]), genomic data (e.g., microarray data [175, 176, 177]), proteomic
data (e.g., PPI data [18, 19, 67, 14]), metabolomic data (e.g., metabolic
pathways [178, 179]) and transcriptomic data (e.g., RNA-Sequencing data
[180, 181, 182]), have been used to improve our understanding of the un-
derlying mechanisms of human diseases. Since various types of biological
data reside in diverse repositories, data integration has become crucial, as
it not only provides a comprehensive view of data, but also enables further
exploration of biological knowledge by efficiently mining and analysing these
large-scale data.
One of the major tasks of biological data integration is to collect and
combine heterogeneous data from different repositories. Repositories such
as the OMIM database [64] for phenotype-genotype associations; the Bi-
oGRID database [30] for PPIs and genetic interactions; the NHGRI GWAS
catalog [73] for GWAS data; KEGG [54] and Reactome [55] for biologi-
cal pathways, are very valuable for biological knowledge discovery. Many
studies in data integration collected information from these repositories and
developed computational methods to gain novel biological insights into hu-
man diseases. Franke et al. (2006) [183] integrated information derived
from PPIs, co-expression data, GO annotations and biological pathways,
and developed a Bayesian framework to reconstruct a functional human
gene network. They applied this network to rank positional candidate genes
for various heritable disorders on the basis of the functional interactions of
disease genes. Also by using a na¨ıve Bayes classifier, Linghu et al. (2009)
[184] constructed an integrated human functional linkage network from dif-
ferent datasets to prioritise disease candidate genes and infer associations
between phenotypically dissimilar disease pairs. Ahn et al. (2011) [185]
integrated PPIs, genetic interactions, gene regulation pathways and mRNA
expression data to classify cancer-related genes. Specifically, they identified
a prostate cancer-specific network of which interactions showed different be-
haviour between tumour and normal samples. Alcaraz et al. (2012) [186]
combined a human PPI network with gene expression data and genome-scale
DNA methylation profiles, and developed a software framework to discover
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connected sub-networks which contained genes that were mainly dysregu-
lated in most cases studied. There are also many other integration-based
approaches that have been successfully applied to predict protein functions
[187, 188, 189], to mine disease-specific pathways [190, 186], to infer disease-
gene relationships [191, 183, 149, 192, 184, 193, 185] and to reposition drugs
[194, 82, 83] from multiple heterogeneous data sources.
We propose to uncover novel associations between diseases via biological
data integration. An accurate classification of human diseases is essential
in consideration of reliable diagnosis and treatment. However, current clas-
sification of human diseases is mainly derived from the similarity of clinical
phenotypes. It has been widely recognised that current disease classification
lacks sensitivity in identifying preclinical diseases and specificity in defin-
ing disease unequivocally [157]. During the past decade, some studies have
been proposed to improve our understanding of the relationship between
diseases using large-scale biological data [65, 66, 67, 81, 132, 57, 140, 141].
Since most of these studies mainly focused on only one type of biological
data (especially genetic data such as OMIM and GWAS data), we believe
an integration-based approach that takes advantage of various types of bi-
ological data will provide further insights into disease relationships.
In this chapter, we integrated different types of biological data collected
from diverse repositories, including disease-gene associations, disease-chemical
associations, biological pathways and GO annotations, to gain further un-
derstanding of human diseases and their relationships. In particular, we
integrated these data into a heterogeneous network, where nodes are bio-
entities and edges between nodes represent their associations. To uncover
novel disease associations, we developed a computational approach to mea-
sure the similarity between diseases, and constructed an integrated disease
network. Our integration-based similarity measure was systematically eval-
uated against the hierarchical tree of the MeSH classification system 1 and a
statistical measure of disease co-occurrence in the literature. Furthermore,
we presented a case study of Crohn’s disease to illustrate how the inte-
grated disease network could be used to improve our current understanding
of disease relationships.
1http://www.nlm.nih.gov/mesh/
89
5.2. Methods
5.2.1. Data collection
We integrated different types of large-scale biological data, including disease-
gene associations, disease-chemical associations, biological pathways and
GO annotations. These data were collected from a number of repositories.
Since different repositories may use different disease naming schemes, we
mapped all diseases annotated in these data to MeSH terms for a correct
integration. Details of data sources and mapping approaches are described
below.
Disease-gene associations
Disease-gene associations were collected from three repositories: CTD [68],
FunDO [163] and the NHGRI GWAS catalog [73].
CTD provides curated disease-gene associations that were extracted from
the published literature by CTD curators, or were derived from OMIM
[64]. We downloaded disease-gene associations from CTD in July 2013, and
collected 21,625 curated associations between 4,286 diseases (annotated by
MeSH terms) and 6,940 genes.
FunDO contains DO2 annotations of the human genome extracted from
the NCBI GeneRIF database3. We used the latest stable version of FunDO
(released in October 2008), which contained gene annotations for 1,854 dis-
eases (annotated by DO IDs). We then mapped DO IDs to MeSH terms
by using the mapping provided in DO version 3 (the latest stable version,
released in May 2007). After mapping, the dataset contained 1,255 dis-
eases (mapped from 1,528 DO IDs), 4,886 genes and 22,879 disease-gene
associations.
GWAS catalog collects associations between traits (or diseases) and SNPs
identified by GWAS studies. We downloaded GWAS catalog data in August
2013. Similar to Sanseau et al. (2012) [84], we eliminated unreplicated
associations and associations with p-value higher than 10−7 to minimise
false-positives. Diseases annotated in GWAS catalog were manually mapped
to MeSH terms. In total, 6,430 associations between 370 diseases and 3,762
2http://disease-ontology.org/
3http://www.ncbi.nlm.nih.gov/gene/about-generif
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genes were collected from the GWAS catalog.
The set of disease-gene associations used in this study was the union set of
CTD, FunDO and GWAS catalog. It contained a total of 48,549 associations
between 4,891 diseases and 11,160 genes.
Disease-chemical associations
Disease-chemical associations used in this study were downloaded from the
CTD database in July 2013. CTD contains both curated and inferred
disease-chemical associations, but we used only curated associations ex-
tracted by CTD curators. In total, we collected 80,225 associations between
3,029 diseases (annotated by MeSH terms) and 8,201 chemicals.
Biological pathways
We collected pathway data from four repositories: KEGG [54], Reactome
[55], WikiPathways [56] and GeneGO4 (i.e., MetaCore from Thomson Reuters).
All of these repositories contain manually curated pathway maps represent-
ing molecular reactions and interactions in a cell. We downloaded path-
way data from the four repositories in September 2013 (pathway data from
GeneGO were licensed). Only human pathways were considered in our
study. In total, we collected 2,319 biological pathways (276 pathways from
KEGG, 1,416 pathways from Reactome, 201 pathways from WikiPathways
and 426 pathways from GeneGO) associated with 9,992 genes.
GO annotations
GO annotations of human were downloaded from the GO database [162]
in September 2013. We removed all IEA annotations as they were compu-
tationally inferred annotations which had not been reviewed by curators.
In total, we collected 123,743 annotations between 13,609 genes and 11,266
GO terms (1,034 cellular component terms, 7,480 biological process terms,
and 2,752 molecular function terms).
4https://portal.genego.com/
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5.2.2. Enrichment analysis
We inferred disease-pathway associations and disease-GO term associations
by identifying pathways and GO terms that were significantly enriched
within the set of genes associated with each disease. The statistical sig-
nificance (p-value) of the enrichment was calculated according to the hy-
pergeometric distribution for sampling without replacement (identical to
one-tailed Fisher’s exact test). For a given disease Di and a given pathway
(or GO term) Pj , let |GDi | be the number of genes associated with Di, |GPj |
be the number of genes annotated with Pj , and |GP | be the total number of
genes in the pathway (or GO annotation) data. If there were x genes anno-
tated with pathway Pj that were associated with Di (thus x = |GDi ∩GPj |),
we computed the p-value of the enrichment (i.e., the probability of observing
the same or higher enrichment purely by chance) as:
p− value = 1−
x−1∑
k=0
(|GPj |
k
)(|GP |−|GPj |
|GDi |−k
)
( |GP |
|GDi |
) (5.1)
Since we used the union of three disease-gene association datasets in our
analysis, we obtained a relatively larger set of annotated genes for each
disease, compared to that obtained by solely using one disease-gene asso-
ciation dataset (which is the case for the study we presented in Chapter
4). It is known that a larger gene list may result in more significant p-
values to slightly enriched pathways (or GO terms) [195]. For this reason,
we used the Bonferroni correction, which is considered as a more stringent
test compared to the others [168], to adjust p-values for multiple compar-
isons. A pathway or a GO term is said to be associated with a disease if
the adjusted p-value is less than 0.05. Through this approach, we identi-
fied 29,432 disease-pathway associations between 1,128 diseases and 1,491
pathways, and 8,614 disease-GO term associations between 999 diseases and
1,714 GO terms.
5.2.3. Disease similarity measure
To uncover associations between diseases from our integrated data, we de-
veloped a novel measure to estimate disease similarity scores. The similarity
measure is based on the vector space model [196, 197], which is frequently
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used in the area of information retrieval. Four types of disease-related data
were used for computing similarity scores, namely disease-gene associations,
disease-chemical associations, disease-pathway associations and disease-GO
term associations. Let E be the set of non-disease elements (i.e., genes,
chemicals, pathways and GO terms) in the integrated dataset. For each
disease Di, we first constructed an |E|-dimensional vector ~Di, called Di’s
signature, to represent information we gained for Di:
~Di =
(
wE0 × f(Di, E0), ..., wEk × f(Di, Ek), ..., wE|E|−1 × f(Di, E|E|−1)
)
(5.2)
where f(Di, Ek) is a function that indicates the presence or absence of the
association between the disease Di and the non-disease element Ek:
f(Di, Ek) =
{
1 if Ek is associated with Di
0 else
and wEk is a weight (also known as the inverse document frequency (idf)
[198]) assigned to Ek. Let D be the set of diseases annotated in the data,
and DEk be the set of diseases associated with Ek. The idf of Ek is defined
as:
wEk = idf(Ek, D) = log
|D|
|DEk |
(5.3)
Assigning the idf as a weight to each non-disease element Ek allows us
to increase the importance of Ek if Ek is rare across all diseases (i.e., Ek is
associated with only a few diseases). Meanwhile, the logarithm in Equation
5.3 prevents our results from being dominated by the most rare non-disease
elements, since the number of associated diseases may greatly differ from
one to another. For a pair of diseases Di and Dj , their similarity can be
measured by the similarity between their corresponding signatures ~Di and
~Dj . Thus we computed the raw similarity score between Di and Dj as the
cosine of the angle θij between ~Di and ~Dj :
cos θij =
~Di · ~Dj
‖ ~Di‖‖ ~Dj‖
(5.4)
If considering only the overlaps of non-disease elements (i.e., the number
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of shared genes, chemicals, pathways and GO terms), a disease Di may
always have a higher similarity score with a complex disease (i.e., a disease
that is caused by a combination of genetic, environmental, and lifestyle
factors [199]) than a monogenic disease (i.e., a disease that is caused by a
single gene). The cosine similarity reduces this bias: it compares disease
signatures ~Di and ~Dj on a normalised space, as it considers only their
orientation and not magnitude. This enables that complex diseases do not
always come out on top in computation of disease similarities.
To further ensure that our results can not be obtained by random chance,
we computed a random similarity score for each pair of diseases Di and Dj
to adjusted their raw similarity score cos θij . Random similarity scores were
computed using a randomisation-based appoarch. We first generated ran-
dom disease-gene association data by rewiring associations: for a disease-
gene association (Dx, Gx), we randomly chose another disease-gene associa-
tion (Dy, Gy), and replaced the two associations by (Dx, Gy) and (Dy, Gx),
if Dx 6= Dy, Gx /∈ GDy and Gy /∈ GDx . This process was repeated until
all disease-gene associations were rewired. We generated random disease-
chemical associations by using a similar approach. Random disease-pathway
associations and random disease-GO term associations were obtained by
running enrichment analysis using the random disease-gene association data.
We then used these random association data to compute a random similar-
ity score for each pair of diseases. This process was repeated 100 times to
generate the average random similarity score γij for each pair of diseases Di
and Dj . Finally we computed the adjusted similarity score for diseases Di
and Dj as:
Similarity(Di, Dj) = max(cos θij − γij , 0) (5.5)
5.3. Results and discussion
5.3.1. Integration of disease-related data
We constructed an Integrated Disease Network (IDN) in which nodes rep-
resent different bio-entities and edges represent the associations between
them. In total the IDN consists 47,342 nodes and 432,660 edges, as shown
in Table 5.1. The IDN was built by integrating large-scale biological data
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Nodes Edges
Bio-entities Number Associations Number
Disease 6,088 Disease-gene 48,549
Gene 18,812 Disease-chemical 80,225
Chemical 8,201 Gene-pathway 142,145
Pathway 2,975 Gene-GO term 123,743
GO term 11,266 Disease-pathway 29,432
Disease-GO term 8,614
Total nodes 47,342 Total edges 432,660
Table 5.1.: Details of the statistics of the IDN.
Figure 5.1.: Flow chart of data integration.
collected from different repositories, as demonstrated in Figure 5.1. All dis-
eases annotated in the repositories were mapped to MeSH disease terms
and all genes were mapped to Entrez gene IDs [200] for the purpose of
integration.
Disease-gene associations were collected from three repositories: CTD,
FunDO and GWAS Catalog. All of these repositories contain curated disease-
gene associations extracted from the literature. The OMIM database is not
included as CTD already contains disease-gene associations derived from
OMIM. GWAS catalog has fewer associations compared to CTD and FunDO
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because GWAS studies have been conducted on only a few diseases thus far.
However, for a specific disease GWAS catalog may contains more informa-
tion than the others (see Section 5.3.3). Since the three repositories focus on
different aspects, the overlap among them is small: only 88 associations are
supported by all three datasets (see Figure A.10 for details). Integrating the
three datasets largely increases the coverage of disease-gene associations.
Disease-pathway and disease-GO term associations were inferred from
disease-gene, gene-pathway, gene-GO term associations by using enrichment
analysis. To investigate how the number of inferred associations deviates
from random, we randomly rewired the associations between diseases and
genes, while keeping the number of associations of each disease and gene un-
changed (also see Section 5.2.3). The randomisation process was repeated
100 times. The average number of disease-pathway (disease-GO term) as-
sociations obtained from random disease-gene associations is 10, 378 ± 223
(2, 395± 57), which is 2.84-fold (3.60-fold) lower than the actual number of
significant disease-pathway (disease-GO term) associations (p-value < 0.01).
These differences suggested that genes associated with the same disease are
more likely to share common biological functions than those associated with
different diseases.
On average, a disease node in the IDN is connected to 9.93 gene nodes,
26.49 chemical nodes, 26.09 pathway nodes and 8.62 GO term nodes; a gene
node in the IDN is connected to 4.35 disease nodes, 14.22 pathway nodes
and 9.09 GO term nodes. The largest connected component of the IDN
contains 46,235 (97.66%) nodes, covering 5,541 (91.02%) diseases. In the
connected network, the average distance between a pair of disease nodes is
4.06 (note that the minimum distance between two diseases is 2). These
results indicate the interconnectedness of human diseases.
5.3.2. Evaluation of similarity measure
We proposed a novel integration-based similarity measure to infer disease-
disease associations from the IDN. In particular, we assigned a score ranging
from 0 to 1 to qualify the strength of the association between a pair of
diseases in the IDN. A similarity score of 0 suggests that the two diseases
are not directly associated: either they have no common neighbours in the
IDN, or their association score is not higher than expected at random (see
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Figure 5.2.: The disease-disease network constructed based on the
integration-based similarity scores. Only the top 1% disease
associations were considered as the edges in the network. Iso-
lated nodes were excluded from the network. Cytoscape 2.8.1
[48] was used for the visualisation. The spring embedding algo-
rithm was chosen as the layout algorithm.
Section 5.2.3). We only considered the 711 diseases that are associated
with at least one gene, one chemical, one pathway and one GO term in
the evaluation. A disease-disease network can be constructed based on
the similarity scores. When considering only the top 1% associations as
the edges in the disease-disease network, the network contains 711 nodes
(including 101 isolated nodes) and 2,525 edges (Figure 5.2). The average
clustering coefficient of this network is 0.419, which is much higher than a
random graph (e.g., for ER random graphs with the same size, the average
clustering coefficient is 0.014± 0.017).
To assess the reliability of our similarity measure, we first evaluated our
similarity measure against the MeSH tree classification (Table A.2) by com-
paring similarity scores of diseases from the same MeSH tree branch to
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those from different MeSH branches. For example, Crohn’s disease and ul-
cerative colitis are both in the ‘Digestive System Diseases’ branch, while
sarcoidosis is in the ‘Hemic and Lymphatic Diseases’ branch. Since sim-
ilarity scores are not normal distributed, we used the Mann-Whitney U
test to compute the statistical significance. We found that diseases from
the same MeSH branch have significantly higher (p-value< 4.9407×10−324)
similarity scores (0.0174±0.0368) than diseases from different MeSH branch
(0.0066± 0.0199).
We further evaluated our similarity measure against the co-occurrence of
disease MeSH terms in the literature. To obtain co-occurrence scores for
all pairs of diseases we analysed, we used a statistical approach proposed
by Li and Agarwal (2009) [57]. In this approach, the co-occurrence score
of a pair of diseases is measured by the statistical significance of their co-
occurrence in the PubMed5 abstracts. We collected 15.29 million abstracts
from PubMed covering articles published from January 1900 to October
2013, and identified disease MeSH terms that were associated with these
abstracts as Major MeSH Headings. Statistical significance of disease co-
occurrence was computed using one-tailed Fisher’s exact test and adjusted
by Benjamini-Hochberg correction (see [57] for details). In total, we col-
lected 8,459 significant co-occurrence associations between the 711 diseases
we evaluated (corrected p-value< 0.05).
Similar to Section 4.3.2, we used ROC curves analysis to investigate the
correlation between our similarity scores with disease co-occurrence scores.
Figure 5.3 and Table A.6 show the ROC curves and AUC values obtained by
evaluating our similarity measure. We found that the correlation between
our integration-based similarity scores and disease co-occurrence scores is
substantially higher than expected at random. In addition, our similarity
measure tends to detect strong disease co-occurrence associations with small
p-values (e.g., p-value < 10−20). When setting the co-occurrence p-value
threshold to 0.05 (i.e., all disease pairs having a co-occurrence p-value less
than 0.05 are considered to be associated, 8,459 pairs in total), we obtained
an AUC value of 0.7580 (Table A.6). This value increased to 0.7646 with
a p-value threshold of 0.01 (7,713 co-occurrence associations in total), and
0.8282 with a p-value threshold of 10−20 (3,330 co-occurrence associations
in total). These results demonstrates the ability of our approach to predict
5http://www.ncbi.nlm.nih.gov/pubmed
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Figure 5.3.: Evaluation of our similarity measure against disease co-
occurrence in the literature. ROC curves were obtained by
using disease-gene associations (gene-based), disease-chemical
associations (chemical-based), disease-pathway associations
(pathway-based), disease-GO term associations (GO-based) or
all four types of associations (integration-based). The p-value
threshold for co-occurrence associations was set to 10−20. AUC
values obtained by using other p-value thresholds can be found
in Table A.6.
co-occurrence associations.
More important, our results reveal the need of data integration for uncov-
ering biological knowledge. We show that using the integration of disease-
related data leads to better performance in recovering disease co-occurrence
associations than solely using one type of data (Figure 5.3 and Table A.6).
Among the four types of disease-related data, disease-gene association seems
to be the most effective in predicting disease associations, followed by disease-
chemical association, disease-pathway association and disease-GO term as-
sociation. However, this result may also suggest that analysing shared bi-
ological pathways and shared GO annotations between diseases may offer
the opportunity to uncover previously undiscovered disease associations.
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Figure 5.4.: Top 20 diseases associated with Crohn’s disease. Diseases are
grouped based on the MeSH tree classification (Table A.2).
Numbers before disease names represent the ranking of asso-
ciation scores (see Table A.7 for the scores). The size of nodes
is inversely proportional to the ranking. The width of edges is
proportional to the association scores. Orange nodes represent
diseases that are associated with Crohn’s disease according to
the literature co-occurrence measure (p-value < 0.05).
5.3.3. Crohn’s disease: a case study
To illustrate how our approaches can be used to improve our current under-
standing of human diseases and their relationships, we present a case study
of Crohn’s disease (MeSH ID: D003424). Crohn’s disease, also known as re-
gional enteritis, is a chronic relapsing inflammatory disorder that can affect
any part of the gastrointestinal tract. It can cause a wide variety of clinical
symptoms, including abdominal pain, diarrhoea, and fever [201]. Recent
studies suggested that Crohn’s disease is an abnormal immune response to
the bacteria in genetically susceptible individuals [202, 203]. However, the
exact underlying cause of Crohn’s disease is still unknown.
In the IDN, Crohn’s disease is linked to 370 gene nodes (40 from CTD, 83
from FunDO, and 285 from GWAS Catalog). Among them only 5 genes are
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reported in all three repositories, including tumor necrosis factor (TNF),
interleukin 10 (IL10), nucleotide-binding oligomerization domain contain-
ing 2 (NOD2), immunity-related GTPase family, M (IRGM) and cyclin Y
(CCNY). These 370 Crohn’s disease associated genes are significantly en-
riched in 120 biological pathways (39 from KEGG, 17 from Reactome, 11
from WikiPathways and 53 from GeneGO) and 47 GO terms (5 cellular
component terms, 39 biological process terms, and 3 molecular function
terms). There are also 25 chemical nodes that are connected to Crohn’s
disease in the IDN.
Figure 5.4 shows the top 20 diseases associated with Crohn’s disease iden-
tified by our approach. 5 diseases among them are also associated with
Crohn’s disease according to the literature co-occurrence measure (p-value
< 0.05). The first two associated diseases are inflammatory bowel diseases
(IBD) and ulcerative colitis (CU), which is not surprising since Crohn’s
disease and CU are considered as two major types of IBD [204]. After
grouping these 20 diseases based on the MeSH tree classification (Table
A.2), we found that 4 out of them are under the same MeSH branch ‘Di-
gestive System Diseases’ with Crohn’s disease. Meanwhile, our results show
that Crohn’s disease is closely related to 5 diseases classified as ‘Bacterial
Infections and Mycoses’ (e.g., leprosy) and 2 diseases classified as ‘Immune
System Diseases’ (e.g., multiple sclerosis). This finding supports the most
widely held hypothesis that Crohn’s disease is caused by the dysfunctional
interaction between the intestinal immune system and a subset of com-
mensal enteric bacteria [202, 203]. Apart from the 5 known disease-disease
associations (i.e., diseases that are associated according to MeSH classifica-
tion or co-occurrence measure), the remaining 15 associations are considered
as novel associations inferred by our approach. High similarity scores and
non-significant co-occurrence p-values of these novel associations suggest
they may have been overlooked in the previous literature.
We further investigated the common underlying mechanisms of Crohn’s
disease and its top 1% associated diseases, including IBD, CU, sarcoido-
sis (SA), psoriatic arthritis (AP), Behc¸et syndrome (BS), leprosy (LE) and
celiac disease (CD). We generated an induced subgraph from the IDN repre-
senting the associations between the 8 diseases and their common annotated
genes (Figure 5.5). TNF6, a gene encodes a multifunctional proinflamma-
6http://www.ncbi.nlm.nih.gov/gene/7124
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Figure 5.5.: The most common genes (represented by round nodes) shared
between Crohn’s disease and its top 7 associated diseases (rep-
resented by hexagon nodes). Only genes that associated with
at least 4 diseases are shown in the figure. The size of a node is
proportional to its degree (i.e., the number of diseases or genes
it associated with). The colour of an edge corresponds to the
disease it connects. A gene node is coloured in orange if its
protein product is a drug target. Cytoscape 2.8.1 [48] was used
for the visualisation.
tory cytokine involved in the regulation of many biological processes such
as cell proliferation, differentiation, and apoptosis, is found to be associated
with all the 8 diseases. It is known that TNF plays an important role in can-
cer and autoimmune diseases and it has been targeted for the treatment of
many diseases including Crohn’s disease [205]. Despite anti-TNF therapies
have been very successful in ameliorating symptoms of autoimmune diseases,
they might be harmful as TNF is still essential for the proper functioning
of the immune system [206]. We also found that many of the genes shared
among the 8 diseases are involved in the regulation of immune response,
e.g., NOD2, interleukin 12B (IL12B), IL10, interferon gamma (IFNG) and
intercellular adhesion molecule 1 (ICAM1). By investigating the biological
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Drug Target Stage Associated diseases
bertilimumab CCL11 Preclinical IBD, LE
ustekinumab IL12B Phase III Clinical Trial IBD, CU, AP, BS, LE, CE
QAX-576 IL13 Phase II Clinical Trial IBD, CU
clazakizumab IL6 Phase II Clinical Trial IBD, CU
PF-4236921 IL6 Phase II Clinical Trial IBD, CU
olokizumab IL6 Phase II Clinical Trial IBD, CU
naltrexone TLR4 Phase II Clinical Trial CU, SA, BS, CE
VT-346 TNF Preclinical All top 7 diseases
ozoralizumab TNF Phase I Clinical Trial All top 7 diseases
XPro-1595 TNF Preclinical All top 7 diseases
certolizumab pegol TNF Launched All top 7 diseases
ESBA-105 TNF Phase II Clinical Trial All top 7 diseases
adalimumab TNF Launched All top 7 diseases
infliximab TNF Launched All top 7 diseases
PF-05230905 TNF Phase I Clinical Trial All top 7 diseases
Table 5.2.: Details of drugs developed for the treatment of Crohn’s disease,
including the drug’s target, current development stage, and dis-
eases that are associated with the target.
pathways shared between these diseases, we found that all of these diseases
are associated with the ‘Cytokines and inflammatory response’ (Wikipath-
ways), the ‘Immune response HSP60 and HSP70/TLR signaling pathway’
(GeneGO) and 7 KEGG disease pathways (Figure A.11 and Figure A.12).
Disease-disease associations uncovered by our approach can be further
used to explore drug repositioning opportunities. Drug repositioning (i.e.,
identifying new disease indications for approved drugs) is considered as one
of the most effective strategies in drug discovery. It can not only substan-
tially reduce the costs and time of drug development, but also provide safer
treatment for patients as it lowers the risk of unexpected toxicity and side
effects [207]. Recently, many computational approaches have been devel-
oped for drug repositioning. These approaches can be roughly classified as
‘drug-based ’ or ‘disease-based’ [208]. ‘Drug-based’ approaches infer repo-
sitioning opportunities from chemical or pharmaceutical perspectives, such
as the chemical properties [209, 210] and molecular activities [211, 212] of
drug compounds. ‘Disease-based’ approaches infer repositioning opportuni-
ties from clinical perspectives, such as drug indications [81, 140, 213] and
side effects [79, 214, 210, 215]. While most of these approaches have focused
on either drug-target or drug-disease associations, only a few studies have
provided an integrated approach to combine different types of associations
for drug repositioning. Sanseau et al. (2012 ) [84] presented an analysis
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that for the first time incorporated drug-target associations with GWAS
data to identify potential drug repositioning opportunities. Another inte-
grated approach for drug repositioning was proposed by Daminelli et al.
(2012) [83]. They constructed a drug-target-disease network by integrating
disease-chemical and drug-target associations, and mined the network for
network motifs of bi-cliques in order to predict disease-drug associations.
However, the major limitation of this approach is that the predictions may
have a high false positive rate since they were inferred solely based on the
network structure.
Here we present an integrated approach for computational drug reposi-
tioning. Four types of associations were used in this approach: disease-drug
associations, disease-gene associations, drug-target associations and disease-
disease associations. In particular, for a pair of associated diseases Di and
Dj , we checked their shared genes (if any) to see whether there existed a gene
which had been targeted by a drug for the treatment of disease Di. If the
drug had not been developed for the treatment of disease Dj , we inferred
an association between that drug and disease Dj . We obtained disease-
drug-target associations from Drugbank 3.0 [76] and Informa Pipeline7 in
November 2013 (data from Informa Pipeline were licensed). From all genes
linked to Crohn’s disease in the IDN, we focused on the 190 genes that are
associated with at least one of the other 7 diseases. 39 out of these genes
encode proteins that are reported as drug targets in Drugbank or Informa
Pipeline. We found that 6 of these druggable genes, including C-C motif
chemokine 11 (CCL11), IL12B, interleukin 13 (IL13), interleukin 6 (IL6),
toll-like receptor 4 (TLR4) and TNF, have been targeted for the treatment
of Crohn’s disease (Table 5.2). The drugs developed for these targets may
provide repositioning opportunities for diseases that are closely associated
with Crohn’s disease. Meanwhile, drugs that have been developed for these
associated diseases may be candidates for the treatment of Crohn’s diseases
(Table 5.3). For example, thalidomide, an immunomodulatory drug that
inhibits the production of TNF, is approved by the U.S. Food and Drug
Administration (FDA) for the treatment of leprosy. Several recent clinical
studies (e.g., [216, 217]) have shown the positive effect of thalidomide on
the remission of Crohn’s disease, supporting the potential repositioning of
thalidomide for Crohn’s disease.
7http://sites.informahealthcare.com/pipeline/
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Drug Target Indication Stage
CI-201 IL12B CU Phase II Clinical Trial
tralokinumab IL13 CU Phase II Clinical Trial
anrukinzumab IL13 CU Phase II Clinical Trial
VT-384 IL18 IBD Preclinical
GSK-1070806 IL18 IBD Phase I Clinical Trial
interleukin-2 IL2RA LE Launched
CR-3294 NOS2 IBD Phase II Clinical Trial
DCAM-253 RIPK2 IBD Preclinical
thalidomide TNF LE Launched
golimumab TNF CU Launched
golimumab TNF SA Phase II Clinical Trial
AG-014 TNF IBD Preclinical
HL-036 TNF IBD Preclinical
etanercept TNF AP Launched
AVX-470 TNF CU Phase I Clinical Trial
Table 5.3.: Details of potential drug repositioning opportunities for Crohn’s
disease, including the drug’s target, disease indication, and cur-
rent development stage.
5.4. Conclusions
In this chapter, we integrated different types of large-scale biological data
collected from different repositories with the aim of gaining further under-
standing of how diseases associated with each other. We constructed a
heterogeneous network to represent the integrated data, where nodes are
bio-entities such as diseases, genes, chemicals, pathways or GO terms, and
edges between nodes represent the associations between these bio-entities.
In addition, we proposed a novel integration-based similarity measure to
infer disease-disease associations from the heterogeneous network. Our sim-
ilarity measure was systematically evaluated against the MeSH tree clas-
sification and a statistical measure of disease occurrence in the literature,
confirming the ability of our approach to recover known disease-disease as-
sociations. We demonstrated how our approach can be used to provide
insights into common underlying mechanisms of diseases and potential drug
repositioning opportunities by presenting a case study of Crohn’s disease.
5.5. Author’s contributions
In the work presented in this chapter, Kai Sun collected all the data (ex-
cluding GeneGO pathways, PubMed abstracts and Informa Pipeline), con-
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structed the IDN, designed and implemented the similarity measure, ran all
the experiments, and performed all the analysis.
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6. Conclusions
6.1. Summary of the dissertation
Gaining biological insights from system-level molecular data requires the de-
velopment of efficient and biologically meaningful algorithms for their anal-
ysis. In this thesis, we presented network-based computational approaches
for uncovering biological knowledge, especially disease-disease associations,
from large-scale biological data, with the aim of providing novel insights
into human diseases and their relationships. In particular, we introduced
novel methods for solving three fundamental problems in biological net-
work analysis, namely network modelling, comparison and integration. Our
methods were applied to analyse diverse system-level biological data such as
PPIs, disease-gene associations, drug-target associations, GO annotations
and biological pathways, and proved to be useful in many biological tasks
such as modelling PPI networks, predicting disease-disease associations and
inferring drug repositioning opportunities.
We exploited systematic measures based on graphlets, which are defined
as small, connected, induced subgraphs of large networks, to analyse the
topology of biological networks. In Chapter 3, we examined the use of
graphlet-based measures for biological network comparison and rebutted
the claim that ‘graphlet-based measures were unstable in regions of low
edge density’. By generating the empirical distributions of GDD agreement
scores, we identified the edge density regions in which the topology of model
networks is ‘unstable’, and showed how graphlet-based measures correctly
detect this topological instability. Moreover, we analysed 18 PPI networks
of different species and showed that these PPI networks had high edge den-
sities thus the ‘unstable’ regions do not affect their analysis. These results
demonstrated the suitability of graphlet-based measures for biological net-
work comparison. We also validated the use of graphlet-based measures for
finding well-fitting random models for PPI networks by using a recently de-
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vised non-parametric statistical test. We showed for the first time that five
viral species, possessing the latest and most complete PPI networks, were
well-fit by several random models. Though the biological significance of
the fits is not immediately clear, we believe the identification of well-fitting
models for viral PPI networks is a stepping stone towards understanding
biological systems.
In Chapter 4, we took advantage of diverse biological data collected from
a number of repositories to gain novel insights into the relationship of hu-
man diseases by considering their underlying biological mechanisms. Un-
like previous studies on disease-disease associations, we used disease-gene
associations obtained from different sources to avoid the bias introduced
by a single dataset. Moreover, we also used the topology of a large-scale
molecular network to examine its use for inferring disease associations. We
applied three disease similarity measures, including standard methods (e.g.,
annotation-based measure) and a novel measure (e.g., topology-based mea-
sure), to estimate similarity scores between diseases. Since most previous
studies were only able to validate part of their predicted associations by
manually mining the literature, we also provided a systematic approach to
assess the quality of computationally predicted disease associations. In par-
ticular, we evaluated disease associations obtained by our measures against
the ICD disease classification system, comorbidity data and GWAS data by
using ROC curve analysis. The strong correlation between our predicted
disease associations and known disease associations indicated the ability of
our approaches to recover known disease associations and the potential to
identify previously undiscovered disease associations.
We further integrated different types of large-scale biological data, in-
cluding disease-gene associations derived from the literature and GWAS
data, disease-chemical associations, biological pathway data and GO an-
notations, to gain more comprehensive understanding of the relationships
between human diseases. In Chapter 5, we constructed a heterogeneous
network in which nodes were bio-entities and edges between nodes repre-
sented their associations. We also extended our disease similarity measures
to an integration-based measure to predict disease associations by mining
the heterogeneous network. Our predictions were systematically evaluated
against a statistical measure of the occurrence of disease MeSH terms in the
literature. In addition, our results showed that using the integrated data led
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to better performance on recovering known disease associations than solely
using one type of data, revealing the need of biological data integration. The
case study of Crohn’s disease well demonstrated the ability our approach to
identify previously undiscovered disease associations, investigate common
underlying mechanisms driving diseases, and infer drug repositioning op-
portunities. Our approach may also be a very effective knowledge mining
tool, as it was able to survey and summarise a large molecular knowledge
space and still provide direct access to the underlying evidence, which is
particularly important for biological knowledge discovery.
Overall, we believe the methodologies and results presented in this the-
sis can provide novel insights into human diseases and their relationships.
Disease associations inferred by our measures have the potential to improve
our current knowledge of disease diagnosis, prognosis and treatment.
6.2. Future work
There exist several open questions closely related to the work presented in
this thesis, as described below.
6.2.1. Modelling biological networks
Finding a model that represents the structural features of biological net-
works is fundamental to understanding complex biological systems. In
Chapter 3, we showed that current PPI networks of many species were
better modelled by the GEO-GD, SF-GD and STICKY models than other
random network models. The STICKY model appeared to be the best fit-
ting model for the five viral PPI networks we analysed except KSHV (i.e.,
the PPI network of Kaposis sarcoma-associated herpes virus). Meanwhile,
PPI networks of Arabidopsis thaliana, nematode worm and fruit fly were
also best fit by the STICKY model, while the best fitting model of the
human PPI network was the GEO-GD model. Investigating the biologi-
cal reasons for these observations is a subject of future research and may
have important implications for understanding the similarity and diversity
in cellular mechanisms of different species.
Despite these advances in modelling PPI networks, we are still far away
from finding the ‘right’ model where the biological data are generated from.
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When comparing the current yeast and human PPI networks with the six
random network models discussed in Chapter 3, none of these models per-
fectly fit the data since there is no overlap between the data-vs-model and
model-vs-model distributions. Further refinement of random models is ex-
pected to better describe the structure of biological networks and could
be used for assessing confidence levels of existing data and predicting new
interactions to guide biological experiments in a time- and cost-efficient way.
The approach we used to model and compare PPI networks can be easily
applied to any types of networks such as metabolic networks, gene regulation
networks, social networks and economic networks to study the structure of
other complex systems.
6.2.2. Integration of molecular interaction networks
In Chapter 4, we introduced a measure to estimate the similarity score
between a pair of diseases based on the topological similarity of their anno-
tated genes in a human PPI network. A potential extension of our topology-
based measure would be to use topological similarities of disease genes in
other molecular intersection networks along with those in the PPI network
to measure disease similarities. For example, we could construct a human
metabolic network, genetic interaction network, cell signalling network, gene
regulation network and PPI network and compute the signature similarities
of disease genes in these networks separately. The topological similarities
between a pair of genes could be measured by the average or maximum
of their signature similarities in different networks. Including topological
information of other molecular interaction networks would provide a more
comprehensive view of the structure of human interactome and might yield
to better understanding of the underlying mechanisms of diseases.
Molecular interaction networks could also be integrated into the heteroge-
neous network discussed in Chapter 5. New algorithms and tools designed
for mining the integrated network which contains different types of molec-
ular interaction data along with disease- and drug-related data might have
many potential uses such as disease gene prioritisation, disease association
predication and drug repositioning.
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6.2.3. Constructing and analysing weighted biological
networks
In the work presented in this thesis, we modelled most of the biological
data as unweighted networks in which an edge between two nodes repre-
sents the presence or absence of the interaction (or association) between
the corresponding bio-entities. For some of these networks, it is possible
to assign weights to their edges based on confidence levels. For example,
a weighted disease-gene association network can be constructed from the
GWAS data by considering the statistical significance of the associations.
How to construct these weighted biological networks, how to apply graphlet-
based measures to analyse their structures, and how to integrate them with
other unweighed networks such as PPI networks, are open research problems
that would be addressed in future research.
6.2.4. Combining similarity measures
We introduced three disease similarity measures to estimate the strength
of disease-disease associations in Chapter 4. The three measures compared
diseases from different aspects: shared gene annotations (annotation-based
measure), common biological processes (function-based measure) and topo-
logical similarity of annotated genes (topology-based). A new measure that
combines these three similarity measures may provide a more comprehensive
view on disease-disease associations. One potential approach is to use super-
vised learning algorithms, such as Na¨ıve Bayes classifier or support vector
machine, to assign the best weights to the similarity scores computed by
using the three similarity measures. Known disease-disease associations de-
rived from standard disease classifications, comorbidity data, GWAS stud-
ies and literature co-occurrence data could be used as training examples to
guide the learning process. The new measure might achieve better perfor-
mances on recovering known disease associations than the three measures
discussed in Chapter 4.
6.2.5. Disease reclassification
Disease-disease associations uncovered in our studies would be further used
to redefine disease classification. For example, a disease-disease association
network would be constructed according to the disease similarity scores,
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and clustering algorithms would be applied to detect the communities in
the network. Diseases that belong to the same cluster might have common
underlying mechanisms and would be grouped under the same category.
It is also possible to use bi-clustering algorithms to discover bi-clusters in
the integrated disease network presented in Chapter 5. Bi-clustering, also
known as co-clustering, is a distinct class of clustering algorithms which is
able to classify the objects and features of a dataset (i.e., rows and columns
of a data matrix) simultaneously [218]. Since the problem of finding a
maximum size bi-cluster has been proven to be NP-complete [218], many
algorithms use heuristic approaches to identify bi-clusters. For example,
BiCluE [219] and Bi-Force [220] algorithms identify bi-clusters by solving
the weighted bi-cluster editing problem, which transforms a given bipartite
graph into a union of disjoint bi-cliques by edge insertions and deletions
with minimal costs for these modifications. In the studies presented in
Chapter 4 and Chapter 5, we mainly focused on quantifying the strength
of disease-disease associations rather than grouping diseases, therefore we
predicted disease associations by using disease similarity measures but not
bi-clustering algorithms. In addition, since most bi-clustering algorithms
were developed for analysing bipartite graphs, extending these algorithms
for analysing heterogeneous networks which contain different types of nodes
and edges is still a subject of future research.
Disease groups identified by clustering algorithms might lead to a novel
integration-based disease classification. Investigating and understanding
the similarity and difference between such classification and existing disease
classifications such as ICD, MeSH and DO, validating the novel classification
via biological experiments and using it to improve current disease diagnosis,
might lead to exciting discoveries in biology and medicine.
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A. Appendix
A.1. Supplementary information for Chapter 2
ICD-9 codes Diseases
001-139 Infectious and parasitic diseases
140-239 Neoplasms
240-279 Endocrine, nutritional and metabolic diseases, and im-
munity disorders
280-289 Diseases of the blood and blood-forming organs
290-319 Mental disorders
320-389 Diseases of the nervous system and sense organs
390-459 Diseases of the circulatory system
460-519 Diseases of the respiratory system
520-579 Diseases of the digestive system
580-629 Diseases of the genitourinary system
630-679 Complications of pregnancy, childbirth, and the puer-
perium
680-709 Diseases of the skin and subcutaneous tissue
710-739 Diseases of the musculoskeletal system and connective
tissue
740-759 Congenital anomalies
760-779 Certain conditions originating in the perinatal period
780-799 Symptoms, signs, and ill-defined conditions
800-999 Injury and poisoning
V01-V91 Supplementary classification of factors influencing
health status and contact with health services
E000-E999 Supplementary classification of external causes of injury
and poisoning
Table A.1.: Three-digit level ICD-9 classification1.
1http://www.icd9data.com/2014/Volume1/default.htm
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MeSH tree ID Diseases
C01 Bacterial infections and mycoses
C02 Virus diseases
C03 Parasitic diseases
C04 Neoplasms
C05 Musculoskeletal diseases
C06 Digestive dystem diseases
C07 Stomatognathic diseases
C08 Respiratory Tract diseases
C09 Otorhinolaryngologic diseases
C10 Nervous system diseases
C11 Eye diseases
C12 Male urogenital diseases
C13 Female urogenital diseases and pregnancy complica-
tions
C14 Cardiovascular diseases
C15 Hemic and lymphatic diseases
C16 Congenital, hereditary, and neonatal diseases and ab-
normalities
C17 Skin and connective tissue diseases
C18 Nutritional and metabolic diseases
C19 Endocrine system diseases
C20 Immune system diseases
C21 Disorders of environmental origin
C22 Animal diseases
C23 Pathological conditions, signs and symptoms
C24 Occupational diseases
C25 Chemically-Induced disorders
C26 Wounds and injuries
F03 Mental disorders
Table A.2.: Top level MeSH tree categories2. Only MeSH categories that
are related to human diseases are listed above.
2http://www.nlm.nih.gov/mesh/trees.html
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A.2. Supplementary information for Chapter 3
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Figure A.1.: GDD agreement vs. edge density when comparing 10, 20, 30,
40, 50 and 100 random model networks to each other with 2000
nodes for ER models (left) and GEO models (right). Error bars
are standard deviations of GDD agreement scores.
Figure A.2.: Visualisation of the human PPI network HS (left) and one of
its highly connected subgraphs (right).
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Figure A.3.: GDD agreement (left) and RGF distance (right) vs. edge den-
sity when comparing 30 random model networks with each
other with 500-10000 nodes for ER, ER-DD (SF-RND), GEO-
GD and STICKY models.
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Figure A.4.: Comparing six random network models with PPI networks of
different species.
141
A.3. Supplementary information for Chapter 4
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
Annotation-based       OMIM
Exp. random
degree≥ 1
degree≥ 3
degree≥ 5
degree≥ 7
degree≥ 10
degree≥ 15
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
Annotation-based       CTD
Exp. random
degree≥ 1
degree≥ 3
degree≥ 5
degree≥ 7
degree≥ 10
degree≥ 15
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
Annotation-based       FunDO
Exp. random
degree≥ 1
degree≥ 3
degree≥ 5
degree≥ 7
degree≥ 10
degree≥ 15
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
Annotation-based       HuGENet
Exp. random
degree≥ 1
degree≥ 3
degree≥ 5
degree≥ 7
degree≥ 10
degree≥ 15
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
Annotation-based       intersection
Exp. random
degree≥ 1
degree≥ 3
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
0.0
0.2
0.4
0.6
0.8
1.0
Tr
ue
 P
os
iti
ve
 R
at
e
Annotation-based       union
Exp. random
degree≥ 1
degree≥ 3
degree≥ 5
degree≥ 7
degree≥ 10
degree≥ 15
Figure A.5.: ROC curves obtained by evaluating the annotation-based mea-
sure against comorbidity. The φ-correlation threshold was set
to 0.06. For each disease-gene association dataset, we evalu-
ated diseases annotated with at least 1, 3, 5, 7, 10, 15 genes,
showing by curves with different colours in each plot. For the
intersection set, only two curves were shown in each plot since
there were no comorbidity associations between diseases anno-
tated with more than 5 genes.
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Figure A.6.: ROC curves obtained by evaluating the function-based mea-
sure against comorbidity. The φ-correlation threshold was set
to 0.06. For each disease-gene association dataset, we evalu-
ated diseases annotated with at least 1, 3, 5, 7, 10, 15 genes,
showing by curves with different colours in each plot. For the
intersection set, only two curves were shown in each plot since
there were no comorbidity associations between diseases anno-
tated with more than 5 genes.
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Figure A.7.: Degree distributions of diseases of the four disease-gene asso-
ciation datasets we analysed. Matlab curve fitting tools were
used to estimate parameters of the best-fitting power-law dis-
tributions to the data.
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Figure A.8.: The distribution of φ-correlation scores.
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Figure A.9.: The overlap of predictions. The x-axis shows the percentage
of predicted associations in all disease pairs we analysed, and
the y-axis shows the percentage of overlap among associations
predicted by the three similarity measures.
PPI Data Nodes Edges
BioGRID version 2.0.56 (released in September 2009) 6,098 18,744
BioGRID version 3.0.68 (released in September 2010) 8,433 29,971
BioGRID version 3.1.80 (released in September 2011) 9,056 37,640
BioGRID version 3.1.93 (released in October 2012) 11,261 66,253
Table A.3.: Details of PPI data obtained from different versions of the Bi-
oGRID database.
A.4. Supplementary information for Chapter 5
Data v. 2.0.56 v. 3.0.68 v. 3.1.80 v. 3.1.93
OMIM 0.7222 0.7431 0.7262 0.8495
CTD 0.7669 0.7524 0.7569 0.7949
FunDO 0.7451 0.7401 0.7274 0.7497
HuGENet 0.6853 0.6965 0.7099 0.7153
Intersection 0.9993 0.9965 0.9962 0.9958
Union 0.7605 0.7685 0.7688 0.7939
Table A.4.: AUC values obtained by evaluating the topology-based simi-
larity measure against comorbidity, using PPI data obtained
from different versions of BioGRID database. The φ-correlation
threshold was set to 0.06 and all diseases annotated with least
3 genes were evaluated. Each evaluation test was run 30 times
to compute the statistics reported in the table.
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Rank Code Disease name Reference
1 239 Neoplasms of unspecified nature PMID: 22278152
2 331 Other cerebral degenerations ICD-9, Comorbidity
3 250 Diabetes mellitus PMID: 23335160
3 256 Ovarian dysfunction PMID: 15351195
5 714 Rheumatoid arthritis and other inflam-
matory polyarthropathies
PMID: 18525447
5 155 Malignant neoplasm of liver and intra-
hepatic bile ducts
PMID: 24148818
7 290 Dementias Comorbidity
8 202 Other malignant neoplasms of lym-
phoid and histiocytic tissue
GWAS
9 335 Anterior horn cell disease ICD-9
9 758 Chromosomal anomalies PMID: 23162423
11 216 Benign neoplasm of skin −
11 401 Essential hypertension PMID: 9403584
11 642 Hypertension complicating pregnancy
childbirth and the puerperium
−
14 710 Diffuse diseases of connective tissue GWAS
15 340 Multiple sclerosis ICD-9, GWAS
16 300 Anxiety, dissociative and somatoform
disorders
PMID: 20479358
16 301 Personality disorders PMID: 22083431
16 305 Nondependent abuse of drugs PMID: 20443774
16 307 Special symptoms or syndromes not
elsewhere classified
PMID: 18181204
20 277 Other and unspecified disorders of
metabolism
PMID: 21645034
21 365 Glaucoma ICD-9
22 295 Schizophrenic disorders GWAS
22 333 Other extrapyramidal disease and ab-
normal movement disorders
ICD-9, Comorbidity,
GWAS
24 362 Other retinal disorders ICD-9
25 577 Diseases of pancreas PMID: 22745701
26 278 Overweight, obesity and other hyperal-
imentation
PMID: 23175195
26 783 Symptoms concerning nutrition
metabolism and development
PMID: 17131227
28 414 Other forms of chronic ischemic heart
disease
GWAS
28 733 Other disorders of bone and cartilage PMID: 23000281
30 042 Human immunodeficiency virus [HIV]
disease
PMID: 19748551
Table A.5.: List of the top 30 diseases associated with Parkinson’s disease
(PD). The topology-based measure was used as the similarity
measure, and FunDO was used as the source of disease-gene
associations.
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Figure A.10.: The overlap of diseases (denoted by ‘D’), genes (denoted by
‘G’) and their associations (denoted by ‘A’) between the three
disease-gene association datasets we integrated.
P-value threshold 5× 10−2 10−2 10−3 10−5 10−10 10−20
Gene-based 0.6914 0.6981 0.6926 0.7171 0.7388 0.7588
Chemical-based 0.7250 0.7293 0.7260 0.7463 0.7647 0.7840
Pathway-based 0.6329 0.6382 0.6335 0.6540 0.6704 0.6857
GO-based 0.5748 0.5768 0.5708 0.5879 0.5971 0.6063
Integration-based 0.7580 0.7646 0.7607 0.7846 0.8064 0.8282
Table A.6.: AUC values obtained by evaluating the integration-based sim-
ilarity measure against disease co-occurrence in the literature.
AUC values obtained by solely using disease-gene associations
(gene-based), disease-chemical associations (chemical-based),
disease-pathway associations (pathway-based) or disease-GO
term associations (GO-based) are also listed in the table.
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Disease Score Gene Chemical Pathway GO term
1 IBD 0.2006 0.2124 (1) 0.1879 (2) 0.2039 (72) 0.1249 (40)
2 CU 0.1640 0.1580 (2) 0.1727 (4) 0.2686 (33) 0.1399 (33)
3 SA 0.1429 0.0584 (7) 0.0925 (16) 0.3845 (4) 0.2942 (4)
4 AP 0.1197 0.0643 (6) 0.0434 (76) 0.3005 (18) 0.2962 (3)
5 BS 0.1186 0.0689 (5) 0.0924 (17) 0.3095 (16) 0.2221 (12)
6 LE 0.1145 0.1069 (3) 0.0467 (63) 0.0890 (154) 0.2501 (10)
7 CD 0.1067 0.0777 (4) 0.1829 (3) 0.3424 (8) 0.0360 (144)
8 NN 0.0999 0.0372 (18) 0.0000 (487) 0.3292 (12) 0.2603 (9)
9 BC 0.0970 0.0467 (13) 0.0000 (300) 0.2988 (19) 0.1565 (26)
10 MIN 0.0948 0.0292 (36) 0.0000 (480) 0.4271 (1) 0.0652 (95)
11 RHD 0.0916 0.0172 (73) 0.0000 (548) 0.3856 (3) 0.1192 (47)
12 PE 0.0912 0.0306 (30) 0.0201 (151) 0.2983 (20) 0.2654 (7)
13 PN 0.0908 0.0322 (26) 0.0428 (77) 0.2982 (21) 0.3369 (1)
14 MS 0.0900 0.0522 (10) 0.0514 (53) 0.2847 (25) 0.1458 (30)
15 EN 0.0869 0.0031 (179) 0.0457 (70) 0.3518 (7) 0.0374 (139)
16 LV 0.0859 0.0319 (28) 0.0000 (448) 0.4200 (2) 0.0707 (89)
17 HA 0.0849 0.0205 (60) 0.1099 (11) 0.3121 (15) 0.1928 (17)
18 TP 0.0836 0.0185 (68) 0.0000 (583) 0.3745 (5) 0.1720 (21)
19 SP 0.0835 0.0460 (14) 0.0425 (78) 0.2123 (67) 0.3192 (2)
20 PA 0.0796 0.0043 (168) 0.0000 (515) 0.2296 (55) 0.2396 (11)
Table A.7.: Similarity scores between Crohn’s disease and its top 20 associ-
ated diseases. Similairty scores were obtained by using the in-
tegrated data (the 3rd column, denoted by ‘Score’), or by solely
using one type of disease-related data, namely disease-gene as-
sociations (the 4th column, denoted by ‘Gene’), disease-chemical
associations (the 5th column, denoted by ‘Chemical’), disease-
pathway associations (the 6th column, denoted by ‘Pathway’) or
disease-GO term associations (the 7th column, denoted by ‘GO
term’). Numbers in brackets are ranks of scores. MeSH terms
of diseases are denoted by abbreviations: ‘Inflammatory Bowel
Diseases’ (IBD), ‘Colitis, Ulcerative’ (CU), ‘Sarcoidosis’ (SA),
‘Arthritis, Psoriatic’ (AP), ‘Behcet Syndrome’ (BS), ‘Leprosy’
(LE), ‘Celiac Disease’ (CD), ‘Nasopharyngeal Neoplasms’ (NN),
‘Brucellosis’ (BC), ‘Mycobacterium Infections, Nontuberculous’
(MIN), ‘Rheumatic Heart Disease’ (RHD), ‘Periodontitis’ (PE),
‘Pneumonia’ (PN), ‘Multiple Sclerosis’ (MS), ‘Entamoebiasis’
(EN), ‘Leishmaniasis, Visceral’ (LV), ‘Hepatitis, Autoimmune’
(HA), ‘Tuberculosis, Pulmonary’ (TP), ‘Spondylitis, Ankylos-
ing’ (SP), ‘Parapsoriasis’ (PA).
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Figure A.11.: The most common biological pathways (represented by
rounded rectangle nodes) shared between Crohn’s disease and
its top 7 associated diseases (represented by hexagon nodes).
The size of nodes is proportional to its degree. The color of
an edge corresponds to the disease it connects. The color of
a pathway node is darker if there are more genes associated
with that pathway. Only pathways that associated with at
least 6 diseases are shown in the figure. Cytoscape 2.8.1 [48]
was used for the visualisation.
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Figure A.12.: Associations between the most common genes (represented
by round nodes) and the most common biological pathways
(represented by rounded rectangle nodes). The size of nodes
is proportional to its degree. Only pathways that associated
with at least 6 diseases are shown in the figure. Cytoscape
2.8.1 [48] was used for the visualisation.
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